Generated by All in One SEO v4.9.9, this is an llms.txt file, used by LLMs to index the site.

# Bioventures

UAMS Tech Transfer Office

## Sitemaps

- [XML Sitemap](https://bioventures.tech/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [BioVentures Invites Community to Register for Innovation Day 2026](https://bioventures.tech/bioventures-invites-community-to-register-for-innovation-day-2026/) - Turning promising discoveries into products, companies and technologies that improve lives takes more than great ideas. It takes collaboration between researchers, entrepreneurs, investors, industry partners and the organizations that help move innovation forward. Those connections will be at the heart of BioVentures Innovation Day 2026, taking place August 19 from 8 a.m. to 6 p.m.on the 12th floor of the Jackson T. Stephens
- [Licensing Spotlight: From UAMS Research to NuvOx’s NanO₂ Stroke Program](https://bioventures.tech/licensing-spotlight-from-uams-research-to-nuvoxs-nano₂-stroke-program/) - A technology developed at the University of Arkansas for Medical Sciences (UAMS) and licensed through BioVentures is continuing its path toward the clinic as NanO₂, an investigational oxygen therapeutic being developed by NuvOx Therapeutics for the treatment of acute ischemic stroke. The underlying innovation was discovered by William C. Culp, M.D., Robert D. Skinner, Ph.D., and Evan C. Unger, M.D. and is based on dodecafluoropentane emulsion (DDFPe), a technology
- [BioVentures Welcomes Fourth Cohort to Medical Innovation and Entrepreneurship Honors Track](https://bioventures.tech/bioventures-welcomes-fourth-cohort-to-medical-innovation-and-entrepreneurship-honors-track/) - BioVentures recently welcomed the fourth cohort of participants in the Medical Innovation and Entrepreneurship Honors Track (MIEHT), a four-year honors program that introduces medical students to health care innovation, intellectual property and technology commercialization.
- [AI Hackathon Brings Student Innovators Together to Address HealthCare Challenges](https://bioventures.tech/ai-hackathon-brings-student-innovators-together-to-address-health-care-challenges/) - The University of Arkansas at Little Rock’s AI Hackathon and HealthTech Startup Week brought together some of Arkansas’ most promising young innovators to explore how artificial intelligence can help address real-world health care challenges.
- [BioVentures Team Attends Bio International Convention 2026](https://bioventures.tech/bioventures-team-attends-bio-international-convention-2026/) - Members of the BioVentures team attended the BIO International Convention, held June 22–25 in San Diego, California, joining more than 20,000 biotechnology professionals from around the world.
- [Applications Open for BioVentures' CADET Program](https://bioventures.tech/applications-open-for-bioventures-cadet-program/) - Develop commercialization skills through BioVentures' year-long CADET program. Applications close Aug. 7.
- [New BioVentures Podcast Episode Features Dr. Marie Burdine’s Research on Kidney Transplant Outcomes](https://bioventures.tech/new-bioventures-podcast-episode-features-dr-marie-burdines-research-on-kidney-transplant-outcomes/) - BioVentures has released a new podcast episode featuring Dr. Marie Burdine, a member of the most recent AR Health Ventures Accelerator cohort. In the episode, she discusses her team's research on a drug designed to reduce delayed graft function (DGF), a complication that can occur following kidney transplantation. DGF affects approximately 30% of kidney transplant
- [Save the Date: BioVentures Innovation Day 2026](https://bioventures.tech/save-the-date-bioventures-innovation-day-2026/) - Join BioVentures Innovation Day 2026 to connect, explore healthcare innovation, and turn discoveries into real-world impact at UAMS.
- [Invention Spotlight: Patent Issued for Personalized Motion-Gated Coronary CTA Scanning Systems and Methods](https://bioventures.tech/invention-spotlight-patent-issued-for-personalized-motion-gated-coronary-cta-scanning-systems-and-methods/) - Newly issued patent enables patient-specific coronary CTA imaging by predicting cardiac motion to improve image quality and accuracy.
- [UA Little Rock Invites Community to AI Hackathon & HealthTech Startup Week Pitches & Demos](https://bioventures.tech/ua-little-rock-invites-community-to-ai-hackathon-healthtech-startup-week-pitches-demos/) - UA Little Rock will host Pitches & Demos for the AI Hackathon & HealthTech Startup Week on Friday, June 12, from 2:00 to 5:00 p.m. at the Engineering & Information Technology Auditorium.
- [Anthony Gunderman Speaks at UAMS Research & Innovation Seminar](https://bioventures.tech/anthony-gunderman-speaks-at-uams-research-innovation-seminar/) - Dr. Anthony Gunderman discussed how engineering and robotics can help address clinical needs during a recent UAMS Research & Innovation seminar.
- [CADET Celebrates Inaugural Cohort with Final Pitch Competition and Showcase ](https://bioventures.tech/cadet-celebrates-inaugural-cohort-with-final-pitch-competition-and-showcase/) - BioVentures celebrated CADET’s inaugural cohort with final pitches, awards, and hands-on training in biomedical entrepreneurship and commercialization.
- [UAMS Team Wins in Toronto with ARGUS, a Smarter Approach to Radiation Safety](https://bioventures.tech/uams-team-wins-in-toronto-with-argus-a-smarter-approach-to-radiation-safety/) - The UAMS team, connected to the Medical Innovation and Entrepreneurship Honors Track (MIEHT), earned both the Biodesign Competition award and the People’s Choice Award for ARGUS, a project designed to better protect physicians during image-guided procedures.
- [Recognizing Fatima Abbas, member of BioVenture's CADET Program, and NanoLit for their Governor's Cup Semifinal Run](https://bioventures.tech/recognizing-fatima-abbas-member-of-bioventures-cadet-program-and-nanolit-for-their-governors-cup-semifinal-run/) - Fatima Abbas and the NanoLit team advanced to the Governor’s Cup semifinals, marking a strong milestone in one of Arkansas’s leading collegiate entrepreneurship competitions.
- [CADET Program Launches with First Cohort at BioVentures](https://bioventures.tech/cadet-program-launches-with-first-cohort-at-bioventures/) - BioVentures launched the first CADET cohort, supporting cancer researchers with training, mentorship, and tools to translate discoveries into real-world impact.
- [BioVentures Supports Innovation at the Governor’s Cup in Little Rock ](https://bioventures.tech/bioventures-supports-innovation-at-the-governors-cup-in-little-rock/) - BioVentures joined the Governor’s Cup in Little Rock, supporting student entrepreneurship and innovation while celebrating emerging talent and the continued strength of Arkansas’s startup ecosystem.
- [New Episode of the BioVentures Podcast with Dr. Kevin Sexton](https://bioventures.tech/new-episode-of-the-bioventures-podcast-with-dr-kevin-sexton/) - In this episode of the BioVentures Podcast, we sit down with Dr. Kevin W. Sexton (surgeon, scientist, and former BioVentures president) to explore his journey from clinical practice to successful health tech innovation. Dr. Sexton shares how early exposure to entrepreneurship and key mentorship moments led him to develop predictive healthcare software later acquired by a
- [Last Days to Apply for MIEHT: Applications Close April 30](https://bioventures.tech/last-days-to-apply-for-mieht-applications-close-april-30/) - There is still time to apply for the Medical Innovation and Entrepreneurship Honors Track (MIEHT), but the deadline is quickly approaching. Applications for the next MIEHT cohort will close on April 30. Hosted by BioVentures at UAMS, MIEHT is a four-year honors track designed for medical students who want to build the skills to identify unmet
- [Invention Spotlight: Copyright Issued for Badge Bandit, a New Multitool for Respiratory Therapy and Clinical Care](https://bioventures.tech/invention-spotlight-copyright-issued-for-badge-bandit-a-new-multitool-for-respiratory-therapy-and-clinical-care/) - Badge Bandit is a respiratory therapist multitool created by Tristan Saunders to improve clinical efficiency, streamline workflows, and support faster care in demanding healthcare settings.
- [HSIE Grand Rounds to Feature Jeff Moran](https://bioventures.tech/hsie-grand-rounds-to-feature-jeff-moran/) - Jeff Moran, Ph.D., CEO of PinPoint Testing LLC, will be the featured speaker at 2 p.m. on Thursday, May 7, 2026, for the Health Sciences Innovation & Entrepreneurship (HSIE) Grand Rounds. His presentation, From Concept to Venture: Building Entrepreneurial Success from the Ground Up, will explore the process of translating ideas into successful ventures, drawing on his extensive experience in analytical toxicology
- [AI Hackathon & HealthTech Startup Week Opens Applications at UA Little Rock](https://bioventures.tech/ai-hackathon-healthtech-startup-week-opens-applications-at-ua-little-rock/) - Applications are open for the AI Hackathon & HealthTech Startup Week at the University of Arkansas at Little Rock, offering hands-on training, certifications, and $20,000 in prizes.
- [Invention Spotlight: Novel Approach to Protein Aggregation in Neurodegenerative Disease](https://bioventures.tech/issued-patent-spotlight-novel-approach-to-protein-aggregation-in-neurodegenerative-disease/) - Congratulations to UAMS inventors Dr. Robert Reis, Dr. Peter Crooks and Dr. Srinivas Ayyadevara on the issuance of a new patent for a promising approach to targeting protein aggregation in neurodegenerative disease. Neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s disease are often linked by one major biological challenge: the buildup of toxic protein aggregates in the brain and central nervous system. While many therapies focus on managing symptoms or addressing downstream effects, there remains a significant need for approaches that target protein aggregation more directly. This newly issued patent covers methods using combretastatin-A4 (CA4) and related analogs to prevent or reduce protein aggregation through compounds that bind glial fibrillary acidic protein (GFAP). The technology represents a new therapeutic direction for aggregation-associated disorders and suggests a potential disease-modifying strategy across multiple neurodegenerative indications. Preclinical studies described in the patent showed encouraging findings across several model systems, including reductions in aggregate burden, decreases in amyloid accumulation, improved disease-related phenotypes, and lifespan extension in nematode models. Together, these results support the potential of a CA4-based platform as a differentiated approach for targeting protein-aggregation pathology in the central nervous system. Inventors Peter Crooks, M.Sc., Ph.D., D.Sc. (Manc), FRSC, FRPharmS, CSci, CChem, Professor Emeritus of Pharmaceutical Sciences at the University of Arkansas for
- [BioVentures and ARise Host Founder’s Forum to Equip UAMS Innovators with Fundraising Strategies  ](https://bioventures.tech/bioventures-and-arise-host-founders-forum-to-equip-uams-innovators-with-fundraising-strategies/) - BioVentures, in partnership with ARise, brought together emerging innovators and entrepreneurs for the first Founder’s Forum, a program designed to support UAMS-affiliated startup founders and teams working to translate research into real-world impact. ARise, a program supporting Arkansas innovators, startups, and entrepreneurs and backed by the Arkansas Economic Development Commission (AEDC), assists tech and tech-enabled companies in reaching new
- [BioVentures Recognizes Student Innovators at UAMS Student Research Day 2026 ](https://bioventures.tech/bioventures-recognizes-student-innovators-at-uams-student-research-day-2026/) - BioVentures presented its Innovation Awards during the 2026 UAMS Student Research Day, recognizing students whose research reflects creativity, scientific excellence, and an interest in translational science. Student Research Day is an annual event that highlights the breadth of research being conducted across UAMS. The event brings together graduate and professional students, postdoctoral fellows, and medical house staff/fellows to
- [BioVentures at the AUTM Annual Meeting 2026 ](https://bioventures.tech/bioventures-at-the-autm-annual-meeting-2026/) - From February 8 to 11, the BioVentures team attended the 2026 AUTM Annual Meeting in Seattle to connect with peers, explore opportunities, and strengthen partnerships.
- [New Patent Enables Enhanced Viral Production Using Engineered Human Cell Lines ](https://bioventures.tech/new-patent-enables-enhanced-viral-production-using-engineered-human-cell-lines/) - What’s the problem? Viruses are essential tools in modern biotechnology, with applications in cancer immunotherapy, gene therapy, and vaccine development. However, producing viruses efficiently at clinical and commercial scale remains a major bottleneck. Many commonly used human cell lines, including the widely adopted A549 line, retain natural antiviral defense mechanisms that limit viral replication, resulting in lower yields and increased manufacturing
- [Applications Now Open for BioVentures’ Medical Innovation and Entrepreneurship Honors Track (MIEHT) ](https://bioventures.tech/applications-now-open-for-bioventures-medical-innovation-and-entrepreneurship-honors-track-mieht/) - The MIEHT program offers structured training in need identification, customer discovery, problem triaging, and iterative solution development. Through seminars, hands-on exploration, and mentorship, students gain practical experience in evaluating clinical challenges and advancing innovative concepts that can improve patient care and healthcare system efficiency.
- [BioVentures Receives 2025 Growth Accelerator Fund Competition Award from the U.S. Small Business Administration ](https://bioventures.tech/bioventures-receives-2025-growth-accelerator-fund-competition-award-from-the-u-s-small-business-administration/) - BioVentures has been selected as one of the awardees of the 2025 Growth Accelerator Fund Competition (GAFC), a program of the U.S. Small Business Administration (SBA) designed to support the growth of science and technology-based startups across the United States. The GAFC program aims to encourage innovative approaches that accelerate the commercialization of emerging technologies
- [BioVentures participates in AUTM University Conference 2025 in New Orleans  ](https://bioventures.tech/bioventures-participates-in-autm-university-conference-2025-in-new-orleans/) - BioVentures participated in the AUTM University Conference 2025, held from October 26–29 in New Orleans. The event brought together professionals from technology transfer offices across the country to exchange knowledge, explore emerging trends, and strengthen collaboration within the tech transfer community. The conference offered a valuable opportunity to learn from experts, exchange best practices, and
- [BioVentures participates in Bio on the Bayou 2025 in New Orleans ](https://bioventures.tech/bioventures-participates-in-bio-on-the-bayou-2025-in-new-orleans/) - BioVentures attended Bio on the Bayou 2025 in New Orleans, a leading regional event that brought together innovators, researchers, and investors to showcase the latest advances in biotechnology, medtech, and health sciences. The conference gathered academic and industry leaders to highlight cutting-edge research and explore new opportunities for collaboration and commercialization. For BioVentures, it was
- [BioVentures Receives Chancellor’s Circle Grant to Expand Student Innovation Training](https://bioventures.tech/bioventures-receives-chancellors-circle-grant-to-expand-student-innovation-training/) - BioVentures LLC has been awarded a $15,000 Chancellor’s Circle Grant to support the initiative “Empowering Student Innovation: Building an Innovation and Entrepreneurship Ecosystem at UAMS.” The program provides UAMS medical and STEM students with hands-on training in intellectual property, startup development, translational research, and commercialization. By integrating scientific research, technology transfer, and entrepreneurial education, it creates structured, experiential pathways
- [UAMS Showcase of Medical Discoveries Highlights BioVentures-Supported Innovation ](https://bioventures.tech/uams-showcase-of-medical-discoveries-highlights-bioventures-supported-innovation/) - The latest UAMS Showcase of Medical Discoveries, held on October 22 at the Jackson T. Stephens Spine & Neurosciences Institute, celebrated the spirit of innovation and entrepreneurship driving research at UAMS. The event featured projects supported by BioVentures LLC, UAMS’ technology transfer office and business incubator, underscoring how discoveries in the lab are evolving into real-world health solutions and startups
- [BioVentures Awarded NIH Grant to Launch CADET Program for Cancer Researchers ](https://bioventures.tech/bioventures-awarded-nih-grant-to-launch-cadet-program-for-cancer-researchers/) - The NIH-funded CADET program, administered by BioVentures, will provide cancer researchers with the entrepreneurial training and mentorship needed to bring lab discoveries to patients. Applications are open until October 31.
- [Immersive Distraction Therapy: A New Way to Reduce Surgical Anxiety ](https://bioventures.tech/immersive-distraction-therapy-a-new-way-to-reduce-surgical-anxiety/) - Newly granted patent: U.S. Patent No. 12,370,338 B2, “Immersive Distraction Therapy.
- [BioVentures to Join the UAMS Showcase of Medical Discoveries ](https://bioventures.tech/bioventures-to-join-the-uams-showcase-of-medical-discoveries/) - Join us on October 22, from 4–6 PM at the Jack Stephens Spine Institute (12th Floor) for the next UAMS Showcase of Medical Discoveries, focused on UAMS intellectual property and innovations. The event will feature technologies developed by UAMS researchers and supported through BioVentures, offering a look at discoveries with the potential to improve health
- [OncoRock Therapeutics Launches at BioVentures ](https://bioventures.tech/oncorock-therapeutics-launches-at-bioventures/) - We were excited to host the kickoff meeting for one of our newest startups, OncoRock Therapeutics, right here at BioVentures! OncoRock is a biotechnology startup dedicated to transforming academic discoveries into impactful cancer treatments. Their capital-efficient model focuses on acquiring promising university assets, de-risking them through preclinical studies and early-phase clinical trials, and then partnering
- [We’re Hiring: Research Program Manager  ](https://bioventures.tech/were-hiring-research-program-manager/) - Do you have a passion for advancing scientific innovation through program leadership? BioVentures is looking for a Research Program Manager to help us build the future of biomedical entrepreneurship and translational research in Arkansas. This role is perfect for someone who thrives at the intersection of science, strategy, and operations. What you’ll do: • Lead
- [Dr. Megan Reed Awarded the Susan Riley Keyes Memorial Fellowship ](https://bioventures.tech/dr-megan-reed-awarded-the-susan-riley-keyes-memorial-fellowship/) - We’re proud to share that our Senior Licensing Associate, Megan Reed PhD, MBA has been selected as a 2025 recipient of the Susan Riley Keyes Memorial Fellowship from the AUTM Foundation. This highly competitive fellowship supports early-career technology transfer professionals through: • Mentorship from seasoned leaders in the field • Specialized training in invention evaluation,
- [A New Approach to Overcome Immunotherapy Resistance ](https://bioventures.tech/a-new-approach-to-overcome-immunotherapy-resistance/) - Newly granted patent: U.S. Patent No. 12,268,674 B2, “Mi-2β Inhibitor as an Immunotherapy Agent” What’s the problem? Immune checkpoint therapies, such as anti-PD-1 antibodies (e.g. Keytruda, Opdivo), have transformed cancer treatment. Yet many patients either don’t respond at all or eventually develop resistance. This limits their long-term effectiveness, leaving a major gap in oncology care.
- [BioVentures to Participate in the TRI Research Expo 2025 ](https://bioventures.tech/bioventures-to-participate-in-the-tri-research-expo-2025/) - BioVentures will be present at the Translational Research Institute (TRI) Research Expo 2025, taking place Wednesday, September 10, from 4:00 to 6:00 p.m. CDT at the Reynolds Institute on Aging, First Floor. The Expo brings together more than 50 research services across UAMS, providing investigators with the opportunity to explore resources, build connections, and learn
- [HSE Grand Rounds to Feature Dr. Stefanie Kennon-McGill](https://bioventures.tech/hse-grand-rounds-to-feature-dr-stefanie-kennon-mcgill/) - Stefanie Kennon-McGill, Ph.D., Senior Program Manager at BioVentures LLC, will be the featured speaker at 2 p.m. Wednesday, August 27, for the Health Sciences Entrepreneurship Grand Rounds. The topic will be “Leveraging Commercialization to Further Your Impact.” Join us at the Winthrop P. Rockefeller Cancer Institute, 10th Floor, Betsy Blass Conference Room. The UAMS community and public are welcome to
- [From Disclosure to Market: How the BioVentures Process Works ](https://bioventures.tech/from-disclosure-to-market-how-the-bioventures-process-works/) - Curious how an idea becomes a protected invention at UAMS? At BioVentures, we guide innovators through every step, from disclosure to patent decisions and market strategy. Here's how the process works, what to expect, and how we support you along the way. Table Of Contents Curious how an idea becomes a protected invention at UAMS?
- [BioVentures Supports UAMS M1 Students in PCAR Summer Program](https://bioventures.tech/bioventures-supports-uams-m1-students-in-pcar-summer-program/) - BioVentures supported University of Arkansas for Medical Sciences (UAMS) first-year medical students this summer through the Partnership in Cancer Research (PCAR) program. Over eight weeks, participants worked in multidisciplinary teams to address real-world challenges in cancer prevention, diagnosis, treatment, or survivorship. The program culminated in entrepreneurial pitch presentations to a panel of judges. Three BioVentures
- [A New Antibody Detects a Hidden Cancer Signal ](https://bioventures.tech/a-new-antibody-detects-a-hidden-cancer-signal/) - Newly granted patent: U.S. Patent No. 12,281,171 B2, “Periostin Antibodies and Methods of Using the Same” What’s the problem? Some cancers create a unique “signal” by adding a rare sugar modification to proteins like periostin. This tumor-specific marker could help identify and target cancer, but it's extremely difficult to detect. Traditional tools often miss it because
- [Building Translational Skills: Inside the 2025 BioVentures Internship ](https://bioventures.tech/building-translational-skills-inside-the-2025-bioventures-internship/) - BioVentures’ 2025 interns modernized core data systems and explored how UAMS innovations reach the market, bridging science and business. BioVentures is wrapping up its 2025 Internship Program on August 1, with two standout students who have brought fresh energy and dedication to the office: Carter Horton and Nyera Ali. Carter, a sophomore in Biomedical Engineering
- [Bringing Discoveries to Life: Technology Transfer at UAMS ](https://bioventures.tech/bringing-discoveries-to-life-technology-transfer-at-uams/) - Every breakthrough at the University of Arkansas for Medical Sciences (UAMS) starts the same way: a question, an experiment, a spark of insight. Yet fewer than 10% of academic discoveries are ever licensed, and even fewer become commercial products, because the gap between lab work and real-world adoption is wider than it looks. That’s where
- [BioVentures at the 2025 Arkansas Commercialization Retreat](https://bioventures.tech/bioventures-at-the-2025-arkansas-commercialization-retreat/) - BioVentures recently took part in the 2025 Arkansas Commercialization Retreat, held June 2–4 at the Winthrop Rockefeller Institute. Organized by the University of Arkansas’ Office of Entrepreneurship and Innovation, this annual event brings together faculty and graduate students from across the state—including UAMS, U of A, UALR, ASU, and UAPB—to explore how research can be
- [BioVentures unveils a smarter, faster way to manage invention disclosures at UAMS  ](https://bioventures.tech/bioventures-unveils-a-smarter-faster-way-to-manage-invention-disclosures-at-uams/) - BioVentures LLC has adopted Tradespace, an AI-driven platform built specifically for technology-transfer offices, to streamline invention disclosures and commercialization efforts across UAMS. Beginning this month, all UAMS inventors will submit new inventions through BioVentures’ new portal, powered by Tradespace, via UAMS Single Sign-On at app.tradespace.io. Tradespace replaces the old portal with a transparent, user-friendly experience
- [Innovation Week 2025 Connects Science, Industry, and Opportunity](https://bioventures.tech/innovation-week-2025-connects-science-industry-and-opportunity/) - BioVentures hosted its first annual Innovation Week from May 12–15, 2025, bringing together researchers, startups, industry partners, and investors to explore the future of biomedical innovation at UAMS. The event featured a dynamic lineup of panels, presentations, and networking opportunities across campus, designed to strengthen the bridge between academic research and real-world impact. Over 50 attendees registered
- [Innovation Week Opens in 7 Days — Are You Registered?](https://bioventures.tech/innovation-week-opens-in-7-days-are-you-registered/) - In one week, BioVentures will welcome innovators from across UAMS and beyond for Innovation Week 2025. Four days of ideas, insight and industry connection on the UAMS Main Campus in Little Rock. Whether you’re advancing breakthrough research, launching a startup or simply curious about commercialization, this is the place to turn discovery into opportunity. Full agenda details, speaker bios
- [Amy Hopper Swan Joins BioVentures as Strategy Consultant](https://bioventures.tech/amy-hopper-swan-joins-bioventures-as-strategy-consultant/) - Amy Hopper Swan is the founder of Swan Impact Strategies, a consulting firm that helps mission-driven organizations design and deliver high-impact programs. With nearly a decade of experience in entrepreneurship, program management and strategic planning, Amy has supported statewide and national initiatives to expand innovation, secure funding and measure outcomes. Amy will help research and
- [Student Innovators Recognized at Student Research Day ](https://bioventures.tech/student-innovators-recognized-at-student-research-day/) - BioVentures is proud to honor the winners of the inaugural Student Innovator Award, selected at Student Research Day. The Student Innovator Award recognizes student research with the potential for translational and commercial success. The winners received a certificate and a cash prize. First Place: Hayley Sabol (Ph.D., College of Medicine, Graduate Program in Interdisciplinary Biomedical
- [BioVentures Innovation Week to Celebrate Innovation & Entrepreneurship at UAMS ](https://bioventures.tech/bioventures-innovation-week-to-celebrate-innovation-entrepreneurship-at-uams/) - BioVentures invites the UAMS community to Innovation Week, May 12-15, 2025. Designed to showcase innovation, foster industry connections and highlight the pathway from research to commercialization, Innovation Week offers opportunities for everyone from seasoned inventors and those just starting out. Whether you're an entrepreneur, inventor, researcher or industry partner, Innovation Week is your chance to
- [Apply Now: Healthcare Innovation Sprint at UCA](https://bioventures.tech/apply-now-healthcare-innovation-sprint-at-uca/) - Are you a student passionate about solving real-world healthcare challenges? The Healthcare Innovation Sprint, hosted by Arkansas Conductor, is a four-day, all-expenses-paid residential camp for rising juniors, seniors, recent grads, and graduate or doctoral students from Arkansas colleges and universities. Participants will collaborate in interdisciplinary teams to tackle real healthcare problems with mentorship from experts in
- [HSE Grand Rounds to Feature Laura James](https://bioventures.tech/hse-grand-rounds-to-feature-laura-james/) - Laura James, MD, director of the Translational Research Institute and vice chancellor for Clinical and Translational Research at UAMS, will be the featured speaker at 2 p.m. Wednesday, April 9, for the Health Sciences Entrepreneurship Grand Rounds. James, who is co-founder of the rapid acetaminophen-induced liver injury testing company Acetaminophen Toxicity Diagnostics, will speak about
- [BioVentures at the AUTM Annual Meeting](https://bioventures.tech/bioventures-at-the-autm-annual-meeting/) - It was a privilege to join fellow innovators at the AUTM Annual Meeting March 2-5 in National Harbor, Maryland, where we celebrated 50 years of propelling technology transfer forward. BioVentures and our colleagues nationwide remain committed to advancing innovation that transforms the future. The BioVentures team learned about the latest industry trends and ideas for
- [Student Innovator Award to Debut at Student Research Day ](https://bioventures.tech/student-innovator-award-to-debut-at-student-research-day/) - BioVentures will announce the Student Innovator Award on April 17 at Student Research Day. This new opportunity recognizes and supports innovative student research with the potential for translational and commercial success. Visit the BioVentures booth at the event to learn more about intellectual property, patenting, entrepreneurship and commercialization. All Student Research Day participants are eligible
- [HSE Grand Rounds: Luna Acosta](https://bioventures.tech/hse-grand-rounds-luna-acosta/) - The next Health Sciences Entrepreneurship (HSE) Grand Rounds will feature Luna Acosta, MBA, ECM, Director of Technology Transfer and the Catalyst Innovation Center at Arkansas State University.
- [BioVentures Announces Innovator Award for Student Research Day ](https://bioventures.tech/bioventures-announces-innovator-award-for-student-research-day/) - This award will be presented at Student Research Day on Tuesday, Feb. 18, and comes with a cash prize for the winners
- [AR Health Ventures Accelerator Announces 2025 Cohort ](https://bioventures.tech/ar-health-ventures-accelerator-announces-2025-cohort/) - Meet the UAMS Entrepreneurs Selected for 2025 Accelerator Cohort: John Arthur, M.D., Ph.D., Nephrology; Marie Burdine, Ph.D., Biochemistry and Molecular Biology; Zachary Waldrip, Ph.D., Surgical Research.
- [Eric Peterson Named President of BioVentures ](https://bioventures.tech/eric-peterson-named-president-of-bioventures/) - BioVentures is pleased to announce the appointment of Eric Peterson, Ph.D., as president of BioVentures LLC.
- [Chancellor’s Circle Grant Fuels Expansion of Medical Innovation and Entrepreneurship Honors Track ](https://bioventures.tech/chancellors-circle-grant-fuels-expansion-of-medical-innovation-and-entrepreneurship-honors-track/) - The Chancellor’s Circle Grant fuels growth in medical innovation, supporting the next generation of entrepreneurial leaders in healthcare at UAMS.
- [ACTIVE Spotlight: Dexter Caffey, CEO and Founder of Smart Eye Technology Inc.](https://bioventures.tech/active-spotlight-dexter-caffey-ceo-and-founder-of-smart-eye-technology-inc/) - Discover how ACTIVE helped Dexter Caffey’s Smart Eye Technology connect with healthcare leaders, breaking into competitive markets with innovative biometric security.
- [ACTIVE Spotlight: Jamie Johnson, Founder of empowerHERjourney ](https://bioventures.tech/active-spotlight-jamie-johnson-founder-of-empowerherjourney/) - Jamie Johnson wants to empower women by providing confidential, customized support during pregnancy, connecting them with the right resources when they need them the most. But first she realized she needed to empower herself to make her ideas a reality: by gaining entrepreneurial skills backed up by the confidence to forge ahead. Johnson is part
- [Learn About ACTIVE at Virtual Open House ](https://bioventures.tech/learn-about-active-at-virtual-open-house/) - The Arkansas Collaborative for Technological and Innovative Venture Equality (ACTIVE) is hosting two online information session events. Interact live with leadership to learn more about ACTIVE and find out if you are a good candidate for the program.
- [ACTIVE Program Accepting Applications for 2025 Cohort ](https://bioventures.tech/active-program-accepting-applications-for-2025-cohort/) - The Arkansas Collaborative for Technological and Innovative Venture Equality (ACTIVE) is accepting applications for its 2025 cohort. This unique initiative is aimed at Arkansans who have faced social and economic barriers to entrepreneurship, providing them with the tools, mentorship and resources needed to advance health care and health technology innovations. Applications are welcome from UAMS
- [ARHVA Deadline Extended to Oct. 31 for Health Innovation Ideas ](https://bioventures.tech/arhva-deadline-extended-to-oct-31-for-health-innovation-ideas/) - The deadline has been extended for UAMS employees to submit innovative therapeutic or drug discovery ideas to the AR Health Ventures Accelerator (ARHVA) for significant financial and administrative support toward commercialization. Selected projects receive financial grants of up to $50,000 project management, budget allocation and progress tracking. All UAMS employees are eligible to apply, including
- [BioVentures Receives $2.4 Million Grant to Address Maternal, Infant Deaths ](https://bioventures.tech/bioventures-receives-2-4-million-grant-to-address-maternal-infant-deaths/) - BioVentures LLC will receive up to $2.4 million over the next four years to test prevention strategies for reducing high rates of maternal and infant deaths in the Arkansas Delta. The grant from the U.S. Department of Health and Human Services (HHS) will fund a combination of education, training, outreach and preventive health services focusing
- [From Idea to Impact: How IP Powers Public Good](https://bioventures.tech/from-idea-to-impact-how-ip-powers-public-good/) - Join us at 2 p.m. Wednesday, Oct. 16, for Health Sciences Entrepreneurship Grand Rounds, featuring Eric Peterson, Ph.D., BioVentures LLC interim president, at the Winthrop P. Rockefeller Cancer Institute, Betsy Blass Conference Room, 10th Floor. In this session, "From Idea to Impact: How IP Powers Public Good," Peterson will explore the pivotal role of intellectual
- [Explore the Inventor's Handbook: Your Guide to Tech Transfer](https://bioventures.tech/explore-the-inventors-handbook-your-guide-to-tech-transfer/) - Discover essential insights into the tech transfer process with the BioVentures Inventor's Handbook. This resource provides UAMS researchers with valuable information on protecting intellectual property, navigating the patenting process, and understanding the benefits of commercialization. Whether you're a new or experienced inventor, this handbook offers step-by-step guidance to help turn your innovations into impactful products
- [Innovation & Entrepreneurship Honors Track Teaches Med Students to Embrace Problem-Solving](https://bioventures.tech/innovation-entrepreneurship-honors-track-teaches-med-students-to-embrace-problem-solving/) - Medicine is changing rapidly in the face of technology and innovation. Today’s medical students must not only keep up with these changes, they should be prepared to take a leading role. Here with a solution is the Medical Innovation and Entrepreneurship Honors Track (MIEHT), available to medical students in the University of Arkansas for Medical
- [Submit Your Idea: ARHVA Awardees Receive Support Toward Commercialization](https://bioventures.tech/submit-your-idea-arhva-awardees-receive-support-toward-commercialization/) - The AR Health Ventures Accelerator (ARHVA) invites UAMS employees to submit innovative therapeutic or drug discovery ideas for significant financial and administrative support toward commercialization. Selected projects receive financial grants of up to $50,000, project management, budget allocation and progress tracking. This unique support framework allows researchers to focus on their innovations, while ARHVA ensures
- [AR Health Ventures Accelerator Announces Top Three Selected Projects ](https://bioventures.tech/ar-health-ventures-accelerator-announces-top-three-selected-projects/) - AR Health Ventures Accelerator proudly announces its inaugural cohort, funding innovative projects in biofilm inhibition, radiation-responsive cancer therapy, and advanced liver injury detection, marking a significant leap in medical research.
- [HSIE Commercialization Training Program to Receive $950K Over 5 Years](https://bioventures.tech/hsie-commercialization-training-program-to-receive-950k-over-5-years/) - The Health Sciences Innovation and Entrepreneurship (HSIE) Training Program has been awarded a $952,975 grant over five years to continue its pioneering work teaching postdoctoral fellows at UAMS how to commercialize their discoveries.
- [Join the ACTIVE Program: Accelerating Healthcare Entrepreneurship in Arkansas](https://bioventures.tech/join-the-active-program-accelerating-healthcare-entrepreneurship-in-arkansas/) - Empowering Arkansas entrepreneurs in healthcare and health tech. Receive comprehensive support and networking opportunities to accelerate your venture. Apply now to join the 2024 cohort and shape the future of healthcare entrepreneurship. Visit bioventures.tech/active to learn more and apply today!
- [Licensing Agreement with Harmonic Discovery and UCSF for FLT3 Mutated AML Development Program ](https://bioventures.tech/licensing-agreement-with-harmonic-discovery-and-ucsf-for-flt3-mutated-aml-development-program/) - BioVentures has announced a licensing agreement with Harmonic Discovery and UC San Francisco for the development of a new drug
- [Powered Orthotic Device for Hand Extension](https://bioventures.tech/powered-orthotic-device-for-hand-extension/) - Automated, therapeutic device that heats and extends fingers that are curled due to hypertonia from cerebral palsy, stroke, multiple sclerosis, spasticity or other cause
- [Light Sensitive Amblyopia Patch](https://bioventures.tech/light-sensitive-amblyopia-patch/) - Light sensitive patch for the treatment of amblyopia.
- [Antibody-Nanoparticle Conjugates for the Treatment of Drug Abuse](https://bioventures.tech/compositions-and-methods-for-generating-reversion-free-attenuated-and-or-replication-incompetent-vaccine-vectors/) - An antibody composition to treat drug use, drug addiction, and effects of drug use
- [Compositions and Methods for Detecting Sessile Serrated Adenomas/Polyps](https://bioventures.tech/compositions-and-methods-for-detecting-sessile-serrated-adenomas-polyps/) - Platform independent assay to distinguish between sessile serrated adenomas and hyperplastic polyps
- [Unraveling IP, Innovation, and Commercialization - Register Now!](https://bioventures.tech/unraveling-ip-innovation-and-commercialization-register-now/) - As part of the TRI Research Fundamentals Seminar Series. Dr. Kennon-McGill will be sharing her insights on "Intellectual Property, Innovation, and Commercialization".
- [Auscultation Device that Attaches to a Smart Device](https://bioventures.tech/auscultation-device-that-attaches-to-a-smart-device/) - Mechanical device that attaches an auscultation device to a smart device such as a smartphone.
- [AR Health Ventures Accelerator Announces Support for Therapeutic Development Projects](https://bioventures.tech/ar-health-ventures-accelerator-announces-support-for-therapeutic-development-projects/) - Submit your proposals for the AR Health Ventures Accelerator program by September 29th. Apply now!
- [BioVentures Team Strengthens Strategic Direction at 2023 AUTM Central Region Meeting](https://bioventures.tech/bioventures-team-strengthens-strategic-direction-at-2023-autm-central-region-meeting/) - BioVentures strengthens strategic direction at AUTM 2023, bolstering industry connections and insights to propel technology transfer endeavors.
- [Accelerate Your Biomedical Innovation: Join the NIH SBIR/STTR Programs Event](https://bioventures.tech/accelerate-your-biomedical-innovation-join-the-nih-sbir-sttr-programs-event/) - Are you a biomedical entrepreneur or small business in need of resources to accelerate your innovation? If the answer is yes, you're in luck! The National Institute of Health (NIH), Arkansas Small Business and Technology Development Center (ASBTDC), University of Arkansas for Medical Sciences (UAMS), and BioVentures are collaborating to bring you a one-of-a-kind event
- [Investment Opportunities for Researchers in Industry](https://bioventures.tech/investment-opportunities-for-researchers-in-industry/) - Discover the exciting investment opportunities below, offered by leading life science companies: GlaxoSmithKline (GSK) Collaborations The director of Academic Alliances at GSK is willing to evaluate researchers and their departments for collaboration in their specific areas of interest. They are willing to put dollars behind people and expect collaboration. GSK can even offer their clinical
- [BioVentures Launches New System for More Efficient Invention Disclosure and IP Management ](https://bioventures.tech/bioventures-launches-new-system-for-more-efficient-invention-disclosure-and-ip-management/) - BioVentures implements a new software platform to optimize its technology transfer operations, improve the invention disclosure process, and offer better data transparency and tracking capabilities for inventors.
- [<strong>HSIE Fellows Excel in Stu Clark New Venture Championships</strong>](https://bioventures.tech/hsie-fellows-excel-in-stu-clark-new-venture-championships/) - Four Health Sciences Innovation and Entrepreneurship Fellows from the University of Arkansas won second place overall and third in the elevator pitch in the Stu Clark New Venture Championships at the University of Manitoba. The competition, focused on entrepreneurship and innovation, had over $60,000 in cash prizes and allowed participants to connect with other entrepreneurs, investors, and business leaders from their industrie
- [Join us for the BioVentures Commercialization Retreat](https://bioventures.tech/join-us-for-the-bioventures-commercialization-retreat/) - Learn about funding mechanisms and how to commercialize research and clinical innovations. Plus, be one of the first 50 to register and receive a free copy of 'Research to Revenue: A Practical Guide to University Start-Ups'.
- [HSIE scholars win UA pitch competition](https://bioventures.tech/hsie-scholars-win-ua-pitch-competition/) - Four HSIE scholars won the Office of Innovation and Entrepreneurship at the University of Arkansas Seed Funding Pitch Competition, which took place in October. First place went to Gene MassID, whose team members included Megan Reed and Julia Tobacyk, both UAMS HSIE Postdoctoral Fellows. They won a $2,000 prize for future research and development of
- [New Opportunity to Accelerate Innovative Technologies](https://bioventures.tech/new-opportunity-to-accelerate-innovative-technologies/) - The BioVentures Development Award Program is a new funding mechanism designed to accelerate the pace of the development of highly innovative technologies and entrepreneurship activity at the University of Arkansas for Medical Sciences (UAMS).
- [Sound-based spirometer system](https://bioventures.tech/sound-based-spirometer-system/) - A sound-based spirometer system including a spirometer and an electronic device having a microphone. The spirometer includes an air inlet and an air outlet. The spirometer generates a sound as an unknown amount of air passes from the air inlet to the air outlet. The sound is recordable by the microphone, and the electronic device processes the sound to determine the volume and flow rate of the unknown amount of air.
- [Small molecule parg inhibitors and methods of use thereof](https://bioventures.tech/small-molecule-parg-inhibitors-and-methods-of-use-thereof/) - "The present disclosure provides methods of inhibiting PARG in cancer cells, including methods comprising administering a PARG inhibitor that modulates position Tyr795 in PARG. Also provided herein are methods of treating and/or preventing cancer comprising administering a PARG inhibitor. In some embodiments, the PARG inhibitors are of the formula: wherein the variables are defined herein.
- [Device and method for in vivo photoacoustic diagnosis and photothermal purging of infected blood](https://bioventures.tech/device-and-method-for-in-vivo-photoacoustic-diagnosis-and-photothermal-purging-of-infected-blood/) - A method of non-invasively detecting and purging bacterial cells using a modified photoacoustic in vivo flow cytometer device is described herein. In particular, a method of detecting bacterial cells by analyzing photoacoustic pulses emitted in response to laser pulses from a pulsed laser source and/or selectively destroying the detected bacterial cells using a non-linear photothermal response induced by a high-energy laser pulse is described herein.
- [Device and method for in vivo flow cytometry using the detection of photoacoustic waves](https://bioventures.tech/device-and-method-for-in-vivo-flow-cytometry-using-the-detection-of-photoacoustic-waves/) - A photoacoustic flow cytometry (PAFC) device for the in vivo detection of cells circulating in blood or lymphatic vessels is described. Ultrasound transducers attached to the skin of an organism detect the photoacoustic ultrasound waves emitted by target objects in response to their illumination by at least one pulse of laser energy delivered using at least one wavelength. The wavelengths of the laser light pulse may be varied to optimize the absorption of the laser energy by the target object. Target objects detected by the device may be unlabelled biological cells or cell products, contrast agents, or biological cells labeled with one or more contrast agents.
- [Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents](https://bioventures.tech/compositions-and-methods-for-inhibiting-antiapoptotic-bcl-2-proteins-as-anti-aging-agents/) - The present disclosure provides compositions and methods for selectively killing senescent cells, wherein the selective killing of senescent cells delays aging and treats age-related disorders.
- [T cells and bifunctional protein against human papillomavirus](https://bioventures.tech/t-cells-and-bifunctional-protein-against-human-papillomavirus/) - Recombinant T cell clonotypes are provided that express T cell receptor alpha and T cell receptor beta polypeptides with specificity for human papillomavirus (HPV) type 16 E6 protein and that amplify in response to a therapeutic vaccine and traffic to ovarian lesional tissue in a patient whose HPV lesions regressed in response to the vaccine. Recombinant T cells expressing appropriate TCR alpha and beta complimentarity determining sequences for HPV 16 E6 binding and treating HPV-cased cancers are provided. Bifunctional proteins having TCR alpha and beta segments that bind to HPV 16 E6 residues 91-115 and a single chain Fv anti-CD3 antibody domain are provided. These bifunctional proteins can direct T cells to HPV-infected cells.
- [Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof](https://bioventures.tech/compounds-that-induce-degradation-of-anti-apoptotic-bcl-2-family-proteins-and-the-uses-thereof/) - A device and method of using the device to detect the presence and composition of clots and other target objects in a circulatory vessel of a living subject is described. In particular, devices and methods of detecting the presence and composition of clots and other target objects in a circulatory vessel of a living subject using in vivo photoacoustic flow cytometry techniques is described.
- [Device and method for in vivo detection of clots within circulatory vessels](https://bioventures.tech/device-and-method-for-in-vivo-detection-of-clots-within-circulatory-vessels/) - A device and method of using the device to detect the presence and composition of clots and other target objects in a circulatory vessel of a living subject is described. In particular, devices and methods of detecting the presence and composition of clots and other target objects in a circulatory vessel of a living subject using in vivo photoacoustic flow cytometry techniques is described.
- [Indole molecules and use thereof in the inhibition of DNA polymerases](https://bioventures.tech/indole-molecules-and-use-thereof-in-the-inhibition-of-dna-polymerases/) - Compositions and methods for the inhibition of DNA polymerases. The methods and compositions as described herein are useful in the treatment of cancer. In particular, the present disclosure provides compositions comprising one or more of indole-derived compounds useful in treatment of cancers, including those which are resistant to genotoxic therapies.
- [Compositions and methods for the treatment and diagnosis of cancer](https://bioventures.tech/compositions-and-methods-for-the-treatment-and-diagnosis-of-cancer/) - Disclosed herein are RNA methyltransf erase inhibitors and methods of using and making the same. The inhibitors may be used in a method for the treatment of a subject in need of a treatment for a cancer by administering an effective amount of the RNA methyltransferase inhibitor and an effective amount of a DNA damaging agent to the subject.
- [Cst6, cells expressing cst6 and methods of use](https://bioventures.tech/cst6-cells-expressing-cst6-and-methods-of-use/) - The present invention provides methods of treating bone loss or cancer using CST6. In these methods, CST6 may be provided as a recombinant CST6 protein, a polynucleotide construct comprising CST6, or an immune cell expressing CST6 protein.
- [Cells for the production of viruses and methods of using the same](https://bioventures.tech/cells-for-the-production-of-viruses-and-methods-of-using-the-same/) - The present disclosure provides compositions and methods for increasing the production of virus in vitro. Modified cells which are modified to eliminate or reduce as compared to a control cell the activity or expression of a Sterile a motif-domain containing protein 9 (SAMD9) polypeptide are provided. Methods of using these cells are also provided.
- [Nek2 proteolysis targeting chimeras for use in malignant disease](https://bioventures.tech/nek2-proteolysis-targeting-chimeras-for-use-in-malignant-disease/) - This invention describes a small molecule proteolysis targeting chimera (PROTAC) strategy to degrade the NEK2 (Never in Mitosis Related Kinase 2) protein and methods of use thereof. The NEK2 PROTAC consists of three, key regions: a NEK2 ligand to bind the NEK2 protein, a linker region to link the NEK2 ligand to a ligase ligand, and the ligase ligand.
- [Cellulose based Anti-viral Anti-microbial spray coating](https://bioventures.tech/cellulose-based-anti-viral-anti-microbial-spray-coating/) - A cellulose based anti-viral/anti-microbial coating.
- [Methods and systems for predicting the effect of inhaled and infused anesthetics](https://bioventures.tech/methods-and-systems-for-predicting-the-effect-of-inhaled-and-infused-anesthetics/) - Disclosed herein are systems and methods for non-invasively predicting a hemodynamic state and/or an anesthetic depth of a patient, such as a pediatric patient. The method may include receiving a peripheral venous pressure (PVP) waveform from the patient, cleaning the PVP waveform, transforming the PVP waveform into the frequency domain, and automatically predicting the hemodynamic state and/or the anesthetic depth of the patient.
- [Photosensitizer conjugated nanoparticles for radiotherapy enhancement](https://bioventures.tech/photosensitizer-conjugated-nanoparticles-for-radiotherapy-enhancement/) - Among the various aspects of the present disclosure is the provision of compositions and methods for targeted treatment of cancers or neoplasms. In particular, the present disclosure is directed to a photodynamic system comprising a nanoparticle conjugated to a photosensitizer that can be activated by an excitation source such as ionizing radiation or other forms of electromagnetic energy.
- [Compositions and methods for generating reversion free attenuated and/or replication incompetent vaccine vectors](https://bioventures.tech/compositions-and-methods-for-generating-reversion-free-attenuated-and-or-replication-incompetent-vaccine-vectors-3/) - Provided herein are methods for generating reversion free attenuated and/or replication incompetent vaccine vectors and their use in vaccine compositions and vaccination. In particular, the use of a codon shuffled helper gene is used to produce compositions comprising replication incompetent virus.
- [Devices and methods for fractionated photoacoustic flow cytometry](https://bioventures.tech/devices-and-methods-for-fractionated-photoacoustic-flow-cytometry/) - A fractionated photoacoustic flow cytometry (PAFC) system and methods for the in vivo detection of target objects in biofluidic systems (e.g., blood, lymph, urine, or cerebrospinal fluid) of a living organism is described. The fractionated system includes a fractionated laser system, a fractionated optical system, a fractionated acoustic system, and combinations thereof. The fractionated laser system includes at least one laser or laser array for pulsing a target object within the circulatory vessel with fractionated focused laser beams. The fractionated optical system separates one or several laser beams into multiple beams in a spatial configuration on the skin above the circulatory vessel of the living organism. The fractionated acoustic system includes multiple focused ultrasound transducers for receiving photoacoustic signals emitted by the target object in response to the fractionated laser beams.
- [Dehydroleucodine derivatives and uses thereof](https://bioventures.tech/dehydroleucodine-derivatives-and-uses-thereof/) - The present invention provides dehydroleucodine derivatives. In particular, the present invention provides amine derivatives of dehydroleucodine and methods of using dehydroleucodine and the amine derivatives of dehydroleucodine to inhibit the growth of cancer cells.
- [Piperlongumine analogues and uses thereof](https://bioventures.tech/piperlongumine-analogues-and-uses-thereof/) - The present disclosure provides compositions and methods for selectively killing senescent cells, wherein the composition comprises piperlongumine derivative thereof. The selective killing of senescent cells may delay aging and/or treat age-related disorders.
- [Myxoma virus compositions and methods of use](https://bioventures.tech/myxoma-virus-compositions-and-methods-of-use/) - Mutant Myxoma viruses are provided herein and methods of using these viruses to treat cancer or elicit an interferon response in a subject are also provided. The mutant Myxoma virus is modified to reduce or eliminate the activity or expression of Myxoma virus protein M62 as compared to a control virus. The mutant virus is capable of stimulating an interferon response in subjects after administration and can also lead to inhibition, reduction or elimination of the CD14+ tumor associated macrophage inhibition of CD4+ T cells in a subject having cancer and lead to a change in the tumor microenvironment to treat the cancer or work in combination with other cancer therapeutics to treat the cancer as described herein.
- [Bcl-2 proteins degraders for cancer treatment](https://bioventures.tech/bcl-2-proteins-degraders-for-cancer-treatment/) - The present disclosure provides compositions and methods for selectively killing cancer cells, wherein the composition comprises a compound of Formula (I). The selective killing of cancer cells occurs with an improved potency and safety profile compared to similar compounds. In particular, the compositions and methods of the invention show reduced platelet toxicity and retained or improved toxicity in cancer cells.
- [Hetero-substituted cyclic lactone analogues and uses thereof](https://bioventures.tech/hetero-substituted-cyclic-lactone-analogues-and-uses-thereof/) - The present disclosure provides SL and SL derivatives comprising a polar substituent adjacent to the lactone ring. Additionally, the present disclosure provides methods of using the SL and SL derivatives to inhibit the growth of leukemic cancer cells.
- [Use of amino acid supplementation for improved muscle protein synthesis](https://bioventures.tech/use-of-amino-acid-supplementation-for-improved-muscle-protein-synthesis/) - The present invention encompasses an amino acid composition for stimulating muscle protein synthesis. Further, the present disclosure relates generally to the use of an anabolic amino acid composition for the stimulation of muscle protein synthesis. In particular, disclosed are compositions and methods of using the same for the prevention and/or treatment of a loss of any one of muscle mass, muscle strength, muscle function, and physical function, or any combination thereof, in a mammal, especially an adult mammal. Also provided are kits comprising a composition for the stimulation of muscle protein synthesis and, in certain embodiments, instructions for administration.
- [Periostin antibodies and methods of using the same](https://bioventures.tech/periostin-antibodies-and-methods-of-using-the-same/) - The present inventors have developed antigen-binding reagents and antigen-binding conjugates that recognize a cancer-specific glycan (carbohydrate) modification on the human Periostin protein. Various in vitro and in vivo diagnostic and/or therapeutic methods using these compositions are also disclosed herein specifically for treating cancers that have amplification of the Mgat3 gene.
- [Gep5 model for multiple myeloma](https://bioventures.tech/gep5-model-for-multiple-myeloma/) - The invention provides, inter alia, methods of prognosing a subject with, or suspected of having, multiple myeloma. In certain embodiments, the methods entail testing the gene expression levels of enolase 1 (ENO1), fatty acid binding protein 5 (FABP5), thyroid hormone receptor interactor 13 (TRIP13), transgelin 2 (TAGLN2), and replication factor C (activator 1) 4 (RFC4) in a biological sample isolated from the subject. The invention also provides methods of treatment for multiple myeloma, as well as kits, oligonucleotides, and systems for performing the methods provided by the invention.
- [Use of gene expression profiling to predict survival in cancer patient](https://bioventures.tech/use-of-gene-expression-profiling-to-predict-survival-in-cancer-patient/) - Gene expression profiling in multiple myeloma patients identifies genes that distinguish between patients with subsequent early death or long survival after treatment. Poor survival is linked to over-expression of genes such as ASPM, OPN3 and CKS1B which are located in chromosome 1q. Given the frequent amplification of 1q in many cancers, it is possible that these genes can be used as powerful prognostic markers and therapeutic targets for multiple myeloma and other cancer.
- [Compositions and methods for selectively depleting senescent cells](https://bioventures.tech/compositions-and-methods-for-selectively-depleting-senescent-cells/) - The present disclosure provides compositions and methods for selectively killing senescent cells, wherein the composition comprises piperlongumine (PL) or derivative thereof. The selective killing of senescent cells may delay aging and/or treat age-related disorders.
- [Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling](https://bioventures.tech/diagnosis-prognosis-and-identification-of-potential-therapeutic-targets-of-multiple-myeloma-based-on-gene-expression-profiling/) - Gene expression profiling is a powerful tool that has varied utility. It enables classification of multiple myeloma into subtypes and identifying genes directly involved in disease pathogenesis and clinical manifestation. The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myeloma. It is further contemplated that therapeutic strategies that directly target CKS1B or related pathways may represent novel, and more specific means of treating high risk myeloma and may prevent its secondary evolution.
- [Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection](https://bioventures.tech/non-specific-delayed-type-hypersensitivity-response-to-treat-herpes-simplex-virus-infection/) - A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection.
- [OMA1 activity assay](https://bioventures.tech/oma1-activity-assay/) - The present disclosure relates to methods and compositions for detecting mitochondrial dysfunction. In particular, the disclosure relates to reporter molecules that are cleavable by the zinc metalloprotease Metalloendopeptidase OMA1 (OMA1). In each embodiment, the reporter molecules of the invention are particularly useful for drug discovery and detection of diseases associated with mitochondrial dysfunction.
- [Electrode for peripheral nerve stimulation](https://bioventures.tech/electrode-for-peripheral-nerve-stimulation/) - Devices and methods for peripheral nerve stimulation with an electrode assembly having a lead body with a tapered transition, at least one anchor, and at least one distal lead configured to connect to the lead body are disclosed.
- [Anti-acetaminophen antibodies and acetaminophen protein adducts](https://bioventures.tech/anti-acetaminophen-antibodies-and-acetaminophen-protein-adducts/) - The present disclosure provides isolated antibodies that bind to acetaminophen-protein adducts that are useful in the detection and diagnosis of acetaminophen-induced toxicity.
- [Inhibitors of oxidized low-density lipoprotein receptor 1 and methods of use thereof](https://bioventures.tech/inhibitors-of-oxidized-low-density-lipoprotein-receptor-1-and-methods-of-use-thereof/) - Inhibitors of oxidized low-density lipoprotein receptor 1 (LOX-1), compositions comprising inhibitors of LOX-1, and methods of using thereof are described.
- [Inhibitors of DNA pk and uses thereof](https://bioventures.tech/inhibitors-of-dna-pk-and-uses-thereof/) - The present disclosure relates to compositions and methods for improving the transplantation outcome and/or reducing immune response in a subject. The compositions comprise a DNA-PK inhibitor.
- [Methods of protecting against neurodegeneration](https://bioventures.tech/methods-of-protecting-against-neurodegeneration/) - The disclosure provides a method of preventing or reducing protein aggregates using combretastatin-A4 (CA4) or an analog thereof. The disclosure also provides methods of reducing the risk, delaying the onset, delaying or slowing the progression, or reversing the signs or symptoms of a neurodegenerative (or other age-progressive) disease using a combretastatin-A4 (CA4) or an analog thereof. The combretastatin-A4 (CA4) or an analog thereof may bind glial fibrillary acidic protein (GFAP). The combretastatin-A4 (CA4) or an analog thereof is described by compounds of Formula (I).
- [Inhibition of dendritic cell-driven regulatory T cell activation and potentiation of tumor antigen-specific T cell responses by interleukin-15 and MAP kinase inhibitor](https://bioventures.tech/inhibition-of-dendritic-cell-driven-regulatory-t-cell-activation-and-potentiation-of-tumor-antigen-specific-t-cell-responses-by-interleukin-15-and-map-kinase-inhibitor/) - The invention involves the discovery that if dendritic cells loaded with a tumor antigen are cultured in interleukin-15 (IL-15), or if T cells activated by the dendritic cells are cultured in IL-15, Treg activity that is specific for the tumor antigen is reduced. This reduction in Treg activity results in an increase in anti-tumor immune response. Another embodiment of the invention involves the discovery that incubating dendritic cells with a MAP kinase inhibitor in combination with IL-15 gives synergistic benefits when the dendritic cells are used to activate T cells. Dendritic cell and T cell compositions incubated with IL-15 or a MAP kinase inhibitor are provided.
- [Acetaminophen adducts and methods of use thereof](https://bioventures.tech/acetaminophen-adducts-and-methods-of-use-thereof/) - The present disclosure relates to acetaminophen protein adducts and methods of diagnosing acetaminophen toxicity using the acetaminophen protein adducts.
- [Triazole derivatives of melampomagnolide B and methods of use thereof](https://bioventures.tech/triazole-derivatives-of-melampomagnolide-b-and-methods-of-use-thereof/) - The present disclosure relates to triazole derivatives of melampomagnolide B, their synthesis, and their use as anti-cancer compounds.
- [Method of Coating Surfaces with Nanoparticles for Biological Analysis of Cells](https://bioventures.tech/method-of-coating-surfaces-with-nanoparticles-for-biological-analysis-of-cells/) - A method of coating a surface with nanoparticles for biological analysis of cells that includes the steps of cleaning the surface with an oxidizing acid, treating the surface with an organosilane, coating the surface with nanoparticles, and then growing cells on the surface coated with the nanoparticles. The surface may be a glass surface, a silica-based surface, a plastic-based surface or a polymer-based surface. The nanoparticles may be gold-based nanomaterials.
- [Preparation and use of a composition for prevention and mitigation of the effects of radiation](https://bioventures.tech/preparation-and-use-of-a-composition-for-prevention-and-mitigation-of-the-effects-of-radiation/) - Plant extracts, compositions, pharmaceutical compositions and methods of making and using the same are provided herein. The compositions comprise γ-tocotrienol (GT3) and δ-tocotrienol (DT3) in ratios wherein the DT3 is predominate. The compositions are useful for radioprotection and radiomitigation in subjects in need thereof.
- [Device and method for in vivo noninvasive magnetic manipulation of circulating objects in bioflows](https://bioventures.tech/device-and-method-for-in-vivo-noninvasive-magnetic-manipulation-of-circulating-objects-in-bioflows/) - A device and methods for the non-invasive manipulation and detection of target objects such as cells, pathogens, microparticles, and nanoparticles in vivo using an external magnetic field are described. In one aspect, a device and method for capturing and detecting intrinsically magnetic target objects or target objects labeled with at least one magnetic particle within the area of interest using an in vivo flow cytometer are described.
- [Compositions for and methods of treating and preventing targeting tumor associated carbohydrate antigens](https://bioventures.tech/compositions-for-and-methods-of-treating-and-preventing-targeting-tumor-associated-carbohydrate-antigens/) - Compositions useful to induce anti-TACA immune response and kits comprising the same and methods of using the compositions to treat and prevent cancer are disclosed. Isolated human antibodies which bind to a carbohydrate mimetic peptide and methods of making the same and using the same to treat and prevent cancer are disclosed. Isolated human NK cells useful to kill tumor cells, and isolated human dendritic cells, and methods of making the same and using the same to treat and prevent cancer are disclosed.
- [Disubstituted triazole analogs](https://bioventures.tech/disubstituted-triazole-analogs/) - The present invention relates to disubstituted triazoles, their synthesis, and their use as anti-cancer compounds. In particular, compounds of Formula (I) are provided.
- [Methods and compositions for X-ray induced release from pH sensitive liposomes](https://bioventures.tech/methods-and-compositions-for-x-ray-induced-release-from-ph-sensitive-liposomes/) - Compositions including pH sensitive lipid vesicles comprised of a lipid layer, an agent, and an organic halogen such that the agent is released from the vesicles after exposure to ionizing radiation. Methods of delivering the agent to a target in a subject using the compositions provided herein are also described. The methods allow for controlled release of the agent. The timing of release of the agent from the lipid vesicle may be controlled as well as the location of release by timing and localizing the exposure to ionizing radiation exposure.
- [Methods and compositions for expanding long-term hematopoietic stem cell populations](https://bioventures.tech/methods-and-compositions-for-expanding-long-term-hematopoietic-stem-cell-populations/) - The invention generally features compositions and methods for expanding long term hematopoietic stem cells (HSCs) in a population of cells. In particular, the invention relates to a method of expanding long term HSCs by culturing an initial population of HSCs with macrophages that promote self-renewal of long term HSCs. The expanded cell population provides a source of cells for therapeutic treatments utilizing HSC transplantation.
- [Melampomagnolide B dimers](https://bioventures.tech/melampomagnolide-b-dimers/) - The present disclosure provides dimers of melampomagnolide B (MMB), including carbamate, carbonate, succinic amide, ester and carboxamide dimers of MMB. These derivatives are useful for treating cancer in humans, in particular in treating leukemia, including acute myelogenous leukemia (AML).
- [Combretastatin analogs](https://bioventures.tech/combretastatin-analogs/) - The present invention relates novel heterocyclic analogs of combretastatin, their synthesis, and their use as anti-cancer compounds. In particular, compounds of Formula (I), Formula (II), and Formula (V) are provided.
- [Asymmetrically coated table](https://bioventures.tech/asymmetrically-coated-table/) - A tablet for the controlled release of a drug. The tablet is in the form of an asymmetrically coated tablet so that immediate release or time-delayed release times can be precisely controlled and the extended release slab may provide zero-order or first-order extended release and pulsatile release depending on the excipients used in the tablet formulations.
- [Apparatus, system, and method of processing biopsy specimens](https://bioventures.tech/apparatus-system-and-method-of-processing-biopsy-specimens/) - A biopsy processing system designed to prevent lodging and possible loss of the tissue specimen for analysis. The system includes a biopsy container having a longitudinal wall forming an internal compartment, a biopsy bag attached to an inner surface of the container, a cassette for receiving the biopsy bag, and an automated system for removing the biopsy bag from the biopsy container and placing the biopsy bag in the cassette.
- [Compositions and methods for modulating neuronal degeneration](https://bioventures.tech/compositions-and-methods-for-modulating-neuronal-degeneration/) - The present disclosure provides genetically modified animals and cells comprising a polynucleotide encoding human profilin1. Also provided are methods of assessing the effects of agents in genetically modified animals and cells comprising a polynucleotide encoding human profilin1.
- [Dodecafluoropentane emulsion as a stroke and ischemia therapy](https://bioventures.tech/dodecafluoropentane-emulsion-as-a-stroke-and-ischemia-therapy/) - The present invention provides methods and combinations for reducing the infarct volume in a tissue of a subject undergoing ischemia or at risk of developing ischemia.
- [Methods and kits for isolation and analysis of a chromatin region](https://bioventures.tech/methods-and-kits-for-isolation-and-analysis-of-a-chromatin-region/) - The present invention encompasses methods of identifying proteins and protein modifications of proteins specifically associated with a chromatin.
- [Methods for making tocoflexols and analogues thereof](https://bioventures.tech/methods-for-making-tocoflexols-and-analogues-thereof/) - Methods for the synthesis of tocoflexols of Formula (I) and (II) and a number of related tocol analogs are provided herein. The methods are economical and amenable to large scale production and can be performed using either pure of partially purified tocotrienols as the starting material.
- [Apparatus, system, and method of processing biopsy specimen](https://bioventures.tech/apparatus-system-and-method-of-processing-biopsy-specimen/) - A biopsy pipette with a filter attached in an internal compartment of a pipette designed to prevent lodging and possible loss of the tissue specimen for analysis. A biopsy test tube may be provided with a biopsy bag attached in the internal compartment of the test tube. Further, a biopsy cassette may be provided with an opening configured to receive a pipette. An automated and non-automated system and method of using the biopsy pipette, biopsy test tube, and biopsy cassette in the processing of biopsy specimen is also disclosed.
- [Hapten compounds and compositions and uses thereof](https://bioventures.tech/hapten-compounds-and-compositions-and-uses-thereof/) - The invention generally relates to hapten compounds comprising either (+)methamphetamine or (+)amphetamine conjugated to a linker. Generally speaking, hapten compounds of the invention may be used to elicit an immune response to one or more of (+)methamphetamine, (+)amphetamine, or (+)MDMA.
- [Modulation of the activity of an interleukin 17 receptor-related protein, EVI27, and uses thereof](https://bioventures.tech/modulation-of-the-activity-of-an-interleukin-17-receptor-related-protein-evi27-and-uses-thereof/) - The present invention describes the cloning and molecular and cellular characterization of a novel protein with homology to the IL-17 receptor. The gene was cloned by virtue of its proximity to a common site of retroviral integration in a murine acute myeloid leukemia. The gene described herein possibly codes for a novel interleukin receptor that binds an as yet unidentified cytokine ligand, and may be useful in cancer diagnostics and therapies that rely on immune system modulation.
- [Inhibition of cancer metastasis](https://bioventures.tech/inhibition-of-cancer-metastasis/) - P-Selectin on platelets and endothelium binds cell surface chondroitin sulfate (CS) proteoglycans, which are abundantly and stably expressed on the surface many cancer cells. Binding of the cancer cells through the CS moieties may be blocked to inhibit the interaction of cancer cells with platelets and endothelium. The present inventors disclose compositions and methods for the inhibition of cancer metastasis.
- [Pharmaceutical compositions comprising an anti-teratogenic compound and applications of the same](https://bioventures.tech/pharmaceutical-compositions-comprising-an-anti-teratogenic-compound-and-applications-of-the-same/) - Pharmaceutical compositions comprising anti-teratogenic agents are disclosed. Additionally, pharmaceutical compositions comprising anti-neoplastic agents and anti-teratogenic agents are disclosed. Methods of assessing the teratogenicity of a compound are disclosed. The present invention further comprises applications of the aforementioned compositions and methods.
- [Methods for producing microbubbles](https://bioventures.tech/methods-for-producing-microbubbles/) - The present invention provides methods for the preparation of gas-filled microbubbles, and methods of using for therapeutic and/or diagnostic applications. In particular, the methods of the invention allow for the preparation of gas-filled microbubbles having narrow size distributions and defined ultrasonic properties.
- [Gene expression profiling based identification of genomic signatures of high-risk multiple myeloma](https://bioventures.tech/gene-expression-profiling-based-identification-of-genomic-signatures-of-high-risk-multiple-myeloma/) - method of gene expression profiling to identify genomic signatures linked to survival specific for a disease and a kit that can be used for performing such a method. Also disclosed herein is the use of such a method in classifying the disease into subsets, predicting clinical outcome and survival of an individual, selecting treatment for an individual suffering from a disease, predicting post-relapse risk and survival of an individual, correlating molecular classification of a disease with genomic signature defining the risk group or a combination thereof.
- [Mouth guard](https://bioventures.tech/mouth-guard/) - A mouth guard including a top mouth piece for engaging the top teeth and a bottom mouth piece for engaging the bottom teeth. The mouth guard also includes a central section having one or more ports for receiving an endotracheal tube, oral gastric tube, and/or oral suction tube. In a first preferred embodiment, a top portion of the central section is attached to the top mouth piece, and a bottom portion of the central section is attached to the bottom mouth piece. In a second preferred embodiment, the entire central section is attached to the bottom mouth piece.
- [Use of the aminoalkylindole JWH-073-M4 and related compounds as neutral CB1 receptor antagonists for the treatment of alcoholism, drug abuse, obesity, and obesity-related diseases](https://bioventures.tech/use-of-the-aminoalkylindole-jwh-073-m4-and-related-compounds-as-neutral-cb1-receptor-antagonists-for-the-treatment-of-alcoholism-drug-abuse-obesity-and-obesity-related-diseases/) - Novel alkylindoles that bind tightly to cannabinoid receptors and are neutral antagonists for the cannabinoid 1 receptor and agonists for the cannabinoid 2 receptor are provided. These compounds are useful for treating alcoholism and drug abuse and for treating obesity.
- [Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds](https://bioventures.tech/monoclonal-antibodies-that-selectively-recognize-methamphetamine-and-methamphetamine-like-compounds/) - The invention generally relates to monoclonal antibodies that recognize at least one compound from the group consisting of (+) methamphetamine, (+) amphetamine, and (+) 3,4-methylenedioxymethamphetamine ((+) MDMA). Generally speaking, the monoclonal antibodies do not recognize (−) methamphetamine, (−) amphetamine, or (−) MDMA.
- [Indole compounds for use in treating inflammation and cancer](https://bioventures.tech/indole-compounds-for-use-in-treating-inflammation-and-cancer/) - Provided herein are compounds, comprising Formula (I) or Formula (II), and their pharmaceutically acceptable salts. Also provided are pharmaceutical compositions comprising a pharmaceutically acceptable excipient and at least one compound of Formula (I) and (II), singly or in combination with other pharmaceutically active ingredients, such as anti-inflammatory agents or anticancer agents.
- [Pneumatic Tocodynamometer](https://bioventures.tech/pneumatic-tocodynamometer/) - A pneumatic tocodynamometer having a guard-ring with a thin elastic membrane stretched across a shallow spherical depression trapping a small volume of air in the center of the guard-ring.
- [Gene expression profiling based identification of CKS1B as a potential therapeutic target in multiple myeloma](https://bioventures.tech/gene-expression-profiling-based-identification-of-cks1b-as-a-potential-therapeutic-target-in-multiple-myeloma/) - The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myleoma.
- [Overexpression of Wnt ligands and treatment of lytic bone diseases](https://bioventures.tech/overexpression-of-wnt-ligands-and-treatment-of-lytic-bone-diseases/) - The present invention is drawn to methods of repairing lytic bone lesions and tumor growth in an individual. In this regard, the present invention discloses use of a Wnt ligand either alone or in combination with anti-Wnt signaling antagonist therapy.
- [Classical cannabinoid metabolites and methods of use thereof](https://bioventures.tech/classical-cannabinoid-metabolites-and-methods-of-use-thereof/) - The present invention encompasses classical cannabinoid metabolites and uses thereof.
- [Conductive interstitial thermal therapy device](https://bioventures.tech/conductive-interstitial-thermal-therapy-device/) - An apparatus and method for thermally destroying tumors in which heat is generated by electrical resistance heating conducted to the target tissue. Computerized scanning is used to optimize the geometry of a thermal probe.
- [Use of amino acid supplementation for improved muscle recovery](https://bioventures.tech/use-of-amino-acid-supplementation-for-improved-muscle-recovery/) - The present invention encompasses an amino acid composition for recovery of muscle strength and function.
- [Diagnosis of multiple myeloma on gene expression profiling](https://bioventures.tech/diagnosis-of-multiple-myeloma-on-gene-expression-profiling/) - Gene expression profiling between normal B cells/plasma cells and multiple myeloma cells revealed four distinct subgroups of multiple myeloma plasma cells that have significant correlation with clinical characteristics known to be associated with poor prognosis.
- [p49/STRAP is a novel protein involved in gene regulation and cell proliferation](https://bioventures.tech/p49-strap-is-a-novel-protein-involved-in-gene-regulation-and-cell-proliferation/) - The invention provides isolated p49/STRAP protein, and isolated nucleic acids encoding a p49/STRAP protein. The inventors have discovered a new protein, named p49/STRAP that is expressed in cardiac tissue and other tissues in mammals.
- [Anti-(+)—methamphetamine monoclonal antibodies](https://bioventures.tech/anti-methamphetamine-monoclonal-antibodies/) - The present invention encompasses compositions and methods for effectively treating at least one symptom or sign of methamphetamine use, or for slowing the rate of (+) methamphetamine entry into the brain of a subject.
- [Diagnosis and classification of multiple myeloma](https://bioventures.tech/diagnosis-and-classification-of-multiple-myeloma/) - Gene expression profiling between normal B cells/plasma cells and multiple myeloma cells revealed four distinct subgroups of multiple myeloma plasma cells that have significant correlation with clinical characteristics known to be associated with poor prognosis.
- [Anti-biofilm compositions and methods for using](https://bioventures.tech/anti-biofilm-compositions-and-methods-for-using/) - Polyphenolic compositions derived from a plant that inhibit the formation of a biofilm. Also provided are combinations that comprise at least one phenolic phytochemical and at least one antimicrobial agent that inhibit the growth of an established biofilm.
- [Staphylococcus aureus strain CYL1892](https://bioventures.tech/staphylococcus-aureus-strain-cyl1892/) - This disclosure presents embodiments of novel strains of Staphylococcus aureus that through genetic engineering produce type 5 capsular polysaccharide at greater levels than Staphylococcus aureus strain Reynolds.
- [Melampomagnolide B derivatives](https://bioventures.tech/melampomagnolide-b-derivatives/) - The present disclosure provides derivatives of melampomagnolide B (MMB), including carbonates, carbamates, and thiocarbamates. The derivatives may be synthesized via an MMB triazole intermediate. These derivatives are useful for treating cancer in humans.
- [Compositions and methods for cytoprotection](https://bioventures.tech/compositions-and-methods-for-cytoprotection/) - The present invention provides compositions and methods for cytoprotection. In particular, it provides zinc chelate compositions comprising at least one zinc ion and at least one aminothiol ligand.
- [Diagnosis, prognosis, identification, and classification of multiple myeloma based on gene expression profiling](https://bioventures.tech/diagnosis-prognosis-identification-and-classification-of-multiple-myeloma-based-on-gene-expression-profiling/) - Provided herein is a method for gene expression profiling multiple myeloma patients into distinct subgroups via DNA hybridization and hierarchical clustering analysis of the hybridization data where the results may further be used to identify therapeutic gene targets.
- [Multi-epitope peptide-loaded dendritic cell immunotherapy for cancer](https://bioventures.tech/multi-epitope-peptide-loaded-dendritic-cell-immunotherapy-for-cancer/) - The invention involves peptides of from about 7 to about 50 amino acid residues in length that have epitopes that bind to more than one HLA class II protein and stimulate CD4+ T cells for treatment of cancer from one of three serine proteases overexpressed in ovarian cancer and other cancers—stratum corneum chymotryptic enzyme, matriptase, and hepsin.
- [CA125 gene and its use for diagnostic and therapeutic interventions](https://bioventures.tech/ca125-gene-and-its-use-for-diagnostic-and-therapeutic-interventions/) - The CA125 gene has been cloned and multiple repeat sequences as well as the carboxy terminus have been identified. The CA125 molecule comprises three major domains: an extracellular amino terminal domain (Domain 1); a large multiple repeat domain (Domain 2); and a carboxy terminal domain (Domain 3) which includes a transmembrane anchor with a short cytoplasmic domain.
- [HPV E6 protein T cell epitopes and uses thereof](https://bioventures.tech/hpv-e6-protein-t-cell-epitopes-and-uses-thereof/) - The present invention is directed to the examination of the pattern of immunodominant T cell epitopes in the E6 protein of Human Papilloma virus and its further characterization in terms of its amino acid sequence and Human Leukocyte Antigen restriction.
- [Compositions and Methods for Improved Organ Transplant Outcomes: Tissue Protection During Transport and Storage](https://bioventures.tech/compositions-and-methods-for-improved-organ-transplant-outcomes-tissue-protection-during-transport-and-storage/) - Protection against injury to organs or tissues during pre-transplant storage and transport
- [Alpha-melanocyte stimulating hormone as topical anti-inflammatory agent for the treatment of allergic contact dermatitis and eczema](https://bioventures.tech/alpha-melanocyte-stimulating-hormone-as-topical-anti-inflammatory-agent-for-the-treatment-of-allergic-contact-dermatitis-and-eczema/) - A method is presented for treating an inflammatory skin disorder in a human comprising: topically applying to the skin a composition comprising alpha-melanocyte stimulating hormone (αMSH) or an αMSH analog in an amount effective to reduce skin inflammation in the human.
- [Novel Plasma Biomarker and Marker Profiles for Analysis of Metastatic Disease](https://bioventures.tech/novel-plasma-biomarker-and-marker-profiles-for-analysis-of-metastatic-disease/) - Novel biomarker profile for the determination and management of metastasis to bone of patients with breast cancer.
- [Linear Lipopeptide Paenipeptins and Methods of Using the Same as Antimicrobials and Potentiators](https://bioventures.tech/linear-lipopeptide-paenipeptins-and-methods-of-using-the-same-as-antimicrobials-and-potentiators/) - Linear lipopeptides that are useful as antimicrobial or antibiofilm compositions and potentiators
- [DNA-dependent protein kinase catalytic subunit (DNA-PKcs) inhibition to improve transplantation outcome and reduce immune response](https://bioventures.tech/dna-dependent-protein-kinase-catalytic-subunit-dna-pkcs-inhibition-to-improve-transplantation-outcome-and-reduce-immune-response/) - Use of DNA-PKcs inhibitors to reduce immune response in a subject or reduce the risk of graft rejection in a transplant patient
- [A Novel Antibody Recognizes a Glycan Specific to Lung and Ovarian Cancer](https://bioventures.tech/a-novel-antibody-recognizes-a-glycan-specific-to-lung-and-ovarian-cancer/) - A novel single chain variable fragment antibody recognizes a glycan specific to lung and ovarian cancer
- [Compositions and Methods for Generating Reversion Free, Attenuated and/or Replication Incompetent Vaccine Vectors](https://bioventures.tech/compositions-and-methods-for-generating-reversion-free-attenuated-and-or-replication-incompetent-vaccine-vectors-2/) - This invention provides methods for generating reversion free, attenuated and/or replication incompetent vaccine vectors and their use in vaccine compositions and vaccination.
- [Neurosurgical Device for Immersive Distraction Therapy](https://bioventures.tech/neurosurgical-device-for-immersive-distraction-therapy/) - The present invention is a device that allows a patient who is undergoing neurosurgery to be distracted through a virtual reality environment
- [Endotracheal Tube Cuff with Integrated Sensors](https://bioventures.tech/endotracheal-tube-cuff-with-integrated-sensors/) - Endotracheal tube cuff with integrated sensors to measure the pressure between the tube and the trachea.
- [PIV Monitor for Estimating Anesthetic Depth](https://bioventures.tech/piv-monitor-for-estimating-anesthetic-depth/) - This device analyses venous pressure to estimate anesthetic depth
- [REACH - Reaching Educators and Children](https://bioventures.tech/reach-reaching-educators-and-children/) - Support to manage children’s behaviors & promote social-emotional development.
- [Is my invention patentable? Prior art vs. Competing art](https://bioventures.tech/how-to-know-if-my-invention-is-patentable-prior-art-vs-competing-art/) - Prior and competing art are fundamental to find out if your invention is patentable. Here is why! What is prior art? What is competing art?
- [I have an idea for an invention. What is next?](https://bioventures.tech/i-have-an-idea-for-an-invention-what-is-next/) - You had come up with an idea for an invention? Here's what you can do to make it a reality

## Pages

- [Home](https://bioventures.tech/) - Fostering Innovation to Power Arkansas Healthcare As the technology transfer office of the University of Arkansas for Medical Sciences, BioVentures supports researchers and healthcare startups, driving innovation for a better healthcare future in Arkansas. Learn more Innovation Day 2026 Join BioVentures Innovation Day 2026 to connect, explore healthcare innovation, and turn discoveries into real-world impact
- [CADET](https://bioventures.tech/programs/cadet/) - Cancer and Developing Entrepreneurial Technologies (CADET) Apply Before August 7 The Cancer and Developing Entrepreneurial Technologies (CADET) program equips cancer researchers, clinicians, and trainees with foundational knowledge in healthcare innovation, intellectual property, and commercialization. Hosted by BioVentures, the technology transfer office of UAMS, the program supports participants in translating promising cancer discoveries into real-world impact
- [Programs](https://bioventures.tech/programs/) - Programs and Resources Save the Date: Innovation Day 2026 Join BioVentures Innovation Day 2026 to connect, explore healthcare innovation, and turn discoveries into real-world impact at UAMS. Date: August 19, 2026 Learn More Cancer and Developing Entrepreneurial Technologies CADET is a training program that guides cancer researchers through the process of translating discoveries into
- [Innovation Day 2026](https://bioventures.tech/innovation-day-2026/) - INNOVATION DAY 2026 Where Discovery Meets Opportunity Register for Free REGISTRATIONS OPEN BioVentures Innovation DAY 2026 Jackson T. Stephens Spine & Neurosciences Institute, 12th Floor. August 19, 2026 INNOVATION DAY STARTS IN: 00Days 00Hours 00Minutes 00Seconds About the Event LET'S CELEBRATE UAMS INNOVATION Join us for BioVentures Innovation Day 2026, a one-day event designed to
- [Episode 19 - AR Health Ventures Accelerator Program (Part 6): Extending Longevity of Kidneys Viable for Transplant](https://bioventures.tech/episode-19-ar-health-ventures-accelerator-program-part-6-extending-longevity-of-kidneys-viable-for-transplant/) - In this episode, Dr. Marie Burdine discusses her team's development of a novel drug designed to reduce delayed graft function, a complication that affects about 30% of kidney transplant recipients. DGF occurs when donor kidneys are damaged during transport and fail to function immediately after transplantation, increasing the risk of rejection and prolonged hospitalization. Using
- [About Us](https://bioventures.tech/about-us/) - Empowering Healthcare Innovation and Economic Growth in Arkansas Your Gateway to Research, Intellectual Property, and Industry Collaboration Get in Touch Our Mission Our mission is to foster commercial investment in the development of inventions, discoveries and other work products flowing from the research at UAMS, the Arkansas Children’s Hospital and the local VA Hospital in
- [MIEHT](https://bioventures.tech/programs/mieht/) - Medical Innovation and Entrepreneurship Honors Track (MIEHT) Preparing medical students to become leaders in healthcare innovation Apply Now Resources for Participants The Medical Innovation and Entrepreneurship Honors Track (MIEHT) is an honors program designed for medical students at the University of Arkansas for Medical Sciences (UAMS). The program prepares future physicians to identify unmet clinical needs and develop solutions with real-world impact and commercialization potential. Upon successful completion of
- [Episode 18 – [INVENTOR SPOTLIGHT] Dr. Kevin W. Sexton: Surgeon, Scientist, Innovator](https://bioventures.tech/episode-18-inventor-spotlight-dr-kevin-w-sexton-surgeon-scientist-innovator/) - In this episode of the BioVentures Podcast, we sit down with Dr. Kevin W. Sexton (surgeon, scientist, and former BioVentures president) to explore his journey from clinical practice to successful health tech innovation. Dr. Sexton shares how early exposure to entrepreneurship and key mentorship moments led him to develop predictive healthcare software later acquired by
- [Founders Forum](https://bioventures.tech/founders-forum/) - UAMS Founder's Forum A founder-first community for UAMS startups. Practical support, real conversations, measurable progress. Request to Join Book 1:1 with ARise About A founder-first community for UAMS startups The Founder’s Forum is a curated peer group for UAMS startup founders who want practical help on real business problems. We meet regularly to workshop challenges like customer
- [Annual Reports](https://bioventures.tech/about-us/annual-reports/) - Annual Reports Dive into this year’s results and milestones. Learn about the achievements that shaped last year, our ongoing efforts to drive innovation, and the goals guiding our path forward. Stay informed about the impact we’re making and the direction we’re taking. ↓ Annual Report 2025 ↓ Annual Report 2024
- [Episode 17 - Behind the Build: Creating a Nerve Block Training Model](https://bioventures.tech/episode-17-behind-the-build-creating-a-nerve-block-training-model/) - In this episode, we sit down with Dr. Erica Malone and doctoral nursing student Blakely Coppock to discuss their innovative nerve block training model developed at UAMS. Designed to bridge the gap between low-fidelity simulators and real patient care, their 3D-printed, ultrasound compatible arm provides immediate visual feedback when a nerve block is performed correctly.
- [Contact](https://bioventures.tech/contact/) - Contact Get in touch If you have any questions, comments or suggestions, do not hesitate to contact us. Fill out this form and we will contact you as quickly as possible. Please enable JavaScript in your browser to complete this form. Name * Email * Subject * Comment or Message * Email Send Message
- [Episode 16 - Bridging the Innovation Gap: Academia and Industry Partnerships](https://bioventures.tech/episode-16-bridging-the-innovation-gap-academia-and-industry-partnerships/) - In this episode of the BioVentures Podcast, we sit down with Michael Geranen, Technology Manager at BioVentures, to explore how industry partnerships help transform academic healthcare innovations into real-world patient solutions. The conversation covers the role of technology transfer offices, what industry partners look for in university inventions, common pitfalls to avoid, and how early
- [Inventor's Handbook](https://bioventures.tech/inventors2/inventors-handbook/) - INVENTOR'S HANDBOOK Everything You Need to Know to Navigate the Tech Transfer Process and Protect Your Intellectual Property. Table of Contents Technology Transfer Basics and BioVentures What is Technology Transfer? Technology transfer refers to the process of transferring technology from one organization to another. This can involve transferring intellectual property such as patents, copyrights, and
- [Episode 15 - AR Ventures Accelerator Program (Part 5): Advancing Early Detection of Acute Kidney Injury](https://bioventures.tech/episode-15-ar-ventures-accelerator-program-part-5-advancing-early-detection-of-acute-kidney-injury/) - In this episode, we talk with Dr. John Arthur about his team’s development of a rapid urine test that can predict severe acute kidney injury much earlier than current methods. By identifying a more accurate biomarker, this technology could help doctors intervene sooner, guide dialysis decisions, and even make future drug trials more feasible.
- [Episode 14 - AR Ventures Accelerator Program (Part 4): Harnessing Yeast to Neutralize Bacterial Toxins](https://bioventures.tech/episode-14-ar-ventures-accelerator-program-part-4-harnessing-yeast-to-neutralize-bacterial-toxins/) - In this episode, we talk with Dr. Zach Waldrop about his Arkansas Health Ventures Accelerator (ARHVA) project developing genetically engineered probiotics to treat gastrointestinal diseases. His team modifies a safe yeast strain, Saccharomyces boulardii, to display antibodies that neutralize bacterial toxins, offering a potential alternative to antibiotics. Early lab tests show the engineered yeast can
- [[INVENTOR SPOTLIGHT] Tristan Saunders on Healthcare Innovation](https://bioventures.tech/inventor-spotlight-tristan-saunders-on-healthcare-innovation/) - Meet Tristan Saunders, healthcare professional andinnovator whose unique path from rural Arkansas to the U.S. Air Force to respiratory therapy has inspired a wave of practical healthcare innovations. Saunders shares his unconventional journey from rural Arkansas to military service and into respiratory therapy, describing how his technical training and unique way of thinking (shaped in
- [Episode 12 - Prototype Funding and Development with hDrop Technologies](https://bioventures.tech/episode-12-prototype-funding-and-development-with-hdrop-technologies/) - On this episode of the BioVentures Podcast, we sit down with Adria Abella Villafranca, founder of hDrop Technologies. Adria shares the story of how his experiences as a college tennis player inspired him to create a wearable device that tracks real-time sweat analytics, helping athletes and workers in the heat better understand their hydration needs.
- [News](https://bioventures.tech/news-2/) - Tech transfer blogfor inventors in the healthcare field. Linking research minds with global markets.
- [Episode 11 - Foundations of Tech Transfer for Inventors, Part 2](https://bioventures.tech/episode-11-foundations-of-tech-transfer-for-inventors-part-2/) - In this follow-up episode of the BioVentures Podcast, Dr. John Sherrill explores what happens after intellectual property (IP) is disclosed and protected. Dr. Sherrill breaks down the commercialization journey—from marketing patented technologies and identifying licensees to navigating license types and supporting faculty-led startups. He shares real-world insight into option agreements, exclusive vs. non-exclusive licenses, and
- [Inventors](https://bioventures.tech/inventors/) - Empowering UAMS Innovators At BioVentures, we help inventors and researchers at UAMS to bring groundbreaking discoveries to life. By offering expert guidance on intellectual property protection, commercialization, and startup formation, we bridge the gap between academia and industry transforming innovations into real-world impact. Submit Invention What BioVentures Does for Inventors 01 Identify and Protect Your
- [The Patent Process](https://bioventures.tech/patent-process/) - The Patent Process Welcome, inventor. We are excited to partner with you to develop your idea. We invite you to start the Invention Disclosure through our form. But before you start, we recommend you read this page to learn our process. Important: For your invention to be patentable, it is important not to have made
- [Episode 10 - Commercializing a Clinical Program with HD Nursing (Part 2)](https://bioventures.tech/episode-10-commercializing-a-clinical-program-with-hd-nursing-part-2/) - Dr. Amy Hester, chairwoman and CEO of HD Nursing, shares insights on commercialization, market positioning, and entrepreneurship. She emphasizes the importance of solving a real pain point and understanding customer needs through different programs. She discusses the strategic value of partnerships and financial sacrifices and warns against unnecessary dilution of ownership through early funding.
- [Episode 9 - Foundations of Tech Transfer for Inventors, Part 1](https://bioventures.tech/episode-9-foundations-of-tech-transfer-for-inventors-part-1/) - In this episode of the BioVentures podcast, Dr. John Sherrill, Senior Licensing Associate at BioVentures, discusses the basics of technology transfer, intellectual property, and commercialization at UAMS. He explains how inventions—ranging from drugs and devices to software and curricula—can move from the lab to the marketplace, with patents playing a key role in protecting and
- [Innovation Week](https://bioventures.tech/innovation-week-2025/) - Where Discovery Meets Opportunity INNOVATION WEEK Register Now REGISTRATIONS OPEN BioVentures Innovation Week UAMS Main Campus, Little Rock May 12-15, 2025 INNOVATION WEEK STARTS IN: 00Days 00Hours 00Minutes 00Seconds About the Event LET'S CELEBRATE UAMS INNOVATION Join us for BioVentures Innovation Week, a four-day event designed to celebrate UAMS innovators, foster industry connections and explore
- [BioVentures Board](https://bioventures.tech/bioventures-board/) - Meet the BioVentures Board The BioVentures Advisory Board comprises a select group of individuals from the realms of business, education, philanthropy and the investment community. The Board advises BioVentures on policies and practices to facilitate basic, medical, clinical and translational research; develop information, products and processes resulting from such research; invest and manage assets to
- [Inventors (old)](https://bioventures.tech/inventors2/) - Inventors Bioventures' Pathway to Patents The invention disclosure process can be overwhelming at times, which is why we have broken down the step by step process for you. Here you can read the timeline in a simple and clear way. If you are an inventor, click here to read a more detailed description of the
- [Episode 8 - Commercializing a Clinical Program with HD Nursing](https://bioventures.tech/episode-8-commercializing-a-clinical-program-with-hd-nursing/) - Dr. Amy Hester, Chairwoman and CEO of HD Nursing, shares the story of how her work as a nurse and administrator at UAMS led to the creation of a highly effective fall prevention program. As regulatory and financial pressures around fall-related injuries increased, the program expanded hospital-wide, significantly reducing injury rates. With encouragement from BioVentures
- [Active 2025 Cohort](https://bioventures.tech/active/active-2025-cohort/) - 2025 COHORT Click Me! Click Me! Click Me! Click Me! Click Me! Click Me! Click Me! Click Me! Click Me! Click Me! Click Me! Click Me! Click Me! Click Me! Click Me! Click Me! Nina Harris Founder & CEO, Crown Yours Rx. Nina Harris is a cranial prosthesis specialist and licensed cosmetologist with nine years
- [BioVentures Podcast](https://bioventures.tech/podcast/) - BioVentures Podcast LISTEN NOW Insights on Innovation and Commercialization Welcome to the BioVentures Podcast, where innovation meets opportunity. As the technology transfer office of the University of Arkansas for Medical Sciences (UAMS), BioVentures plays a pivotal role in managing the intellectual property generated at the institution. Our mission is to empower inventors and startups in
- [Active 2024 Cohort](https://bioventures.tech/active/active-2024-cohort/) - 2024 COHORT Click Me! Click Me! Click Me! Click Me! Click Me! Click Me! Click Me! Click Me! Click Me! Click Me! Click Me! Click Me! Click Me! Click Me! Click Me! Click Me! Click Me! Dexter Caffey CEO and Founder, Smart Eye Technology Inc. Dexter Caffey, who earned a bachelor’s degree in finance from
- [Podcast 2 Transcript](https://bioventures.tech/podcast/transcript-episode-2/) - BioVentures Podcast transcript Episode 2 AR Ventures Accelerator Program (Part 1): New Approach to Chemotherapy Using Liposomes Joe Schaffner: Welcome to the BioVentures Podcast, where we discuss all things related to technology transfer, entrepreneurialism, research, intellectual property and innovation. My name is Joe Schaffner, outreach coordinator for BioVentures. Stefanie Kennon-McGill: My name is Stefanie
- [Podcast 1 Transcript](https://bioventures.tech/podcast/transcript-episode-1/) - BioVentures Podcast transcript Episode 1 [Intro music] Joe Schaffner: Welcome to the very first episode of the BioVentures podcast, where we discuss technology transfer, entrepreneurialism, research, intellectual property and all things related to health technology. My name is Joe Schaffner, outreach coordinator for BioVentures, and today we’ll be discussing the Arkansas Collaborative for Technological and
- [ARHVA](https://bioventures.tech/programs/ar-health-ventures-accelerator/) - The AR Health Ventures Accelerator (ARHVA) is a program designed to accelerate the development of therapeutic projects from scientific discovery to commercialization. Focused on advancing biomedical research from the University of Arkansas for Medical Sciences (UAMS), ARHVA provides consultancy, guidance, and funding to selected projects. The program aims to de-risk discoveries and enhance their commercial
- [Hackathon 2024](https://bioventures.tech/hackathon-2024/) - Maternal Health HACKATHON 00Days 00Hours 00Minutes 00Seconds Register Now DATE April 5-7, 2024 Registrations Free & Open LOCATION Little Rock, Arkansas Why Maternal Health? Solving maternal health problems in Arkansas is not just a moral imperative but a critical necessity for the well-being of our state. Healthy mothers are fundamental to the strength of our
- [Submit Invention Disclosure](https://bioventures.tech/submit-invention-disclosure/) - Transform Your Ideas into Impactful Innovations Unleash your innovation’s potential with our expert guidance and resources. Turn your groundbreaking ideas into real-world solutions by submitting your invention disclosure today. More information below. Submit Your Invention Disclosure Invention Disclosure Start the Process Initiating the invention disclosure process is simple and straightforward. Just log in to Wellspring
- [Commercialization Retreat 2023](https://bioventures.tech/commercialization-retreat-2023/) - Innovation Commercialization Retreat 00Days 00Hours 00Minutes 00Seconds Register Now DATE May 5th, 2023 Registrations Free & Open LOCATION Little Rock, Arkansas Join BioVentures and UAMS Research and Innovation for an immersive Commercialization Retreat. Our expert speakers will discuss the importance of commercializing UAMS discoveries to advance patient treatments, as well as share insights on how
- [Startup Tools](https://bioventures.tech/startup-tools/) - Startup Tools Here is our handy list of tools for startups to help get you started and manage your business. Accounting Efficiency Data Communication Operations Design Web / Marketing Funding Accounting Adminsoft, free, ad-supported accounting software Money Manager Ex, open-source, full-featured financial software Wave, financial/accounting/payment/invoicing software Zipbooks, accounting and online invoicing Expensify, expense reporting with
- [Healthcare Software](https://bioventures.tech/technology-healthcare-software/) - Technology Licensing Diagnostic Therapeutic Medical Device Research Tools Copyright Healthcare Software All Diagnostic Therapeutic Medical Device Research Tools Copyright Healthcare Software All Search Do you need more information? Please contact us if you have any questions, or if you would like further information on these or other upcoming BioVentures technologies. Name Company Email Message Send
- [Copyright](https://bioventures.tech/technology-copyright/) - Technology Licensing Diagnostic Therapeutic Medical Device Research Tools Copyright Healthcare Software All Diagnostic Therapeutic Medical Device Research Tools Copyright Healthcare Software All Search REACH – Reaching Educators and Children Support to manage children’s behaviors & promote social-emotional development. Read more » May 4, 2022 Do you need more information? Please contact us if you have
- [Research Tools](https://bioventures.tech/technology-research-tools/) - Technology Licensing Diagnostic Therapeutic Medical Device Research Tools Copyright Healthcare Software All Diagnostic Therapeutic Medical Device Research Tools Copyright Healthcare Software All Search Compositions and Methods for Generating Reversion Free, Attenuated and/or Replication Incompetent Vaccine Vectors This invention provides methods for generating reversion free, attenuated and/or replication incompetent vaccine vectors and their use in vaccine
- [Therapeutic](https://bioventures.tech/technology-therapeutic/) - Technology Licensing Diagnostic Therapeutic Medical Device Research Tools Copyright Healthcare Software All Diagnostic Therapeutic Medical Device Research Tools Copyright Healthcare Software All Search AR Health Ventures Accelerator Announces 2025 Cohort Meet the UAMS Entrepreneurs Selected for 2025 Accelerator Cohort: John Arthur, M.D., Ph.D., Nephrology; Marie Burdine, Ph.D., Biochemistry and Molecular Biology; Zachary Waldrip, Ph.D., Surgical
- [Diagnostic](https://bioventures.tech/technology-diagnostic/) - Technology Licensing Diagnostic Therapeutic Medical Device Research Tools Copyright Healthcare Software All Diagnostic Therapeutic Medical Device Research Tools Copyright Healthcare Software All Search Gene expression profiling based identification of genomic signatures of high-risk multiple myeloma method of gene expression profiling to identify genomic signatures linked to survival specific for a disease and a kit that
- [Medical Device](https://bioventures.tech/technology-medical-device/) - Technology Licensing Diagnostic Therapeutic Medical Device Research Tools Copyright Healthcare Software All Diagnostic Therapeutic Medical Device Research Tools Copyright Healthcare Software All Search Immersive Distraction Therapy: A New Way to Reduce Surgical Anxiety Newly granted patent: U.S. Patent No. 12,370,338 B2, “Immersive Distraction Therapy. Read more » October 9, 2025 Light Sensitive Amblyopia Patch Light
- [Resources, Guidelines and Forms](https://bioventures.tech/resources-guidelines-and-forms/) - Policies and Procedures Faculty and Inventors Rights and Responsibilities Download Distribution of Royalties for Inventions Download How Inventorship is Decided Download Conflict of Interest The fundamental values of BioVentures include the highest standards of research integrity and objectivity. Thus, no conflict of interest on the part of academic staff members can be permitted to influence
- [News](https://bioventures.tech/news/)
- [Frequently Asked Questions (FAQs)](https://bioventures.tech/frequently-asked-questions-faqs/) - FAQs General Who is Bioventures? Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Where does our technology come from? Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Lorem ipsum dolor sit? Accordion Content Invention Evaluation
- [Space Rent Page](https://bioventures.tech/space-rent-page/) - space rental for startups make room for your project Office and Coworking rental to focus on what really matters: your idea. See Spaces Excellent Service Ultricies risus integer sed placerat Delivered With Care Pharetra molestie viverra placerat Secure Payment Euismod laoreet eget turpis platea Office Rent in Little Rock Lab Rent in Little Rock Bioventures
- [Events](https://bioventures.tech/events/)
- [Shop](https://bioventures.tech/shop/)
- [Sample Page](https://bioventures.tech/sample-page/) - This is an example page. It's different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduces them to potential site visitors. It might say something like this: Hi there! I'm a bike messenger

## Categories

- [Uncategorized](https://bioventures.tech/category/uncategorized/)
- [Technology](https://bioventures.tech/category/technology/)
- [Blog](https://bioventures.tech/category/blog/)
- [News](https://bioventures.tech/category/news/)
- [Innovation](https://bioventures.tech/category/news/innovation/)
- [Corporate](https://bioventures.tech/category/news/corporate/)
- [People](https://bioventures.tech/category/news/people/)
- [Strategic](https://bioventures.tech/category/news/strategic/)
- [Education](https://bioventures.tech/category/news/education/)
- [Opportunities](https://bioventures.tech/category/opportunities/)
- [Events](https://bioventures.tech/category/news/events/)
- [ACTIVE](https://bioventures.tech/category/active/)
- [CADET](https://bioventures.tech/category/cadet/)
- [Podcast](https://bioventures.tech/category/podcast/)
- [Programs](https://bioventures.tech/category/programs/)
- [MIEHT](https://bioventures.tech/category/programs/mieht/)

## Tags

- [Diagnostic](https://bioventures.tech/tag/diagnostic/)
- [Therapeutic](https://bioventures.tech/tag/therapeutic/)
- [Research Tools](https://bioventures.tech/tag/research-tools/)
- [Medical Devices](https://bioventures.tech/tag/medical-devices/)
- [Copyrights](https://bioventures.tech/tag/copyrights/)
- [Legal](https://bioventures.tech/tag/legal/)
- [Patent](https://bioventures.tech/tag/patent/)
- [Methods](https://bioventures.tech/tag/methods/)
- [Pharmaceutical](https://bioventures.tech/tag/pharmaceutical/)
- [funding](https://bioventures.tech/tag/funding/)
- [grant](https://bioventures.tech/tag/grant/)
- [bioventures development award program](https://bioventures.tech/tag/bioventures-development-award-program/)
- [award](https://bioventures.tech/tag/award/)
- [invention](https://bioventures.tech/tag/invention/)
- [HSIE](https://bioventures.tech/tag/hsie/)
- [PitchCompetition](https://bioventures.tech/tag/pitchcompetition/)
- [Innovation](https://bioventures.tech/tag/innovation/)
- [University of Arkansas](https://bioventures.tech/tag/university-of-arkansas/)
- [UAMS](https://bioventures.tech/tag/uams/)
- [University of Arkansas for Medical Sciences](https://bioventures.tech/tag/university-of-arkansas-for-medical-sciences/)
- [TRI](https://bioventures.tech/tag/tri/)
- [inventor](https://bioventures.tech/tag/inventor/)
- [invention process](https://bioventures.tech/tag/invention-process/)
- [retreat](https://bioventures.tech/tag/retreat/)
- [event](https://bioventures.tech/tag/event/)
- [research](https://bioventures.tech/tag/research/)
- [university](https://bioventures.tech/tag/university/)
- [commercialization](https://bioventures.tech/tag/commercialization/)
- [Competition](https://bioventures.tech/tag/competition/)
- [system](https://bioventures.tech/tag/system/)
- [startup](https://bioventures.tech/tag/startup/)
- [NIH](https://bioventures.tech/tag/nih/)
- [SBIR/STTR](https://bioventures.tech/tag/sbir-sttr/)
- [SBIR](https://bioventures.tech/tag/sbir/)
- [STTR](https://bioventures.tech/tag/sttr/)
- [AUTM](https://bioventures.tech/tag/autm/)
- [Kansas](https://bioventures.tech/tag/kansas/)
- [network](https://bioventures.tech/tag/network/)
- [opportunities](https://bioventures.tech/tag/opportunities/)
- [development](https://bioventures.tech/tag/development/)
- [knowledge](https://bioventures.tech/tag/knowledge/)
- [intellectual property](https://bioventures.tech/tag/intellectual-property/)
- [technology manager](https://bioventures.tech/tag/technology-manager/)
- [Talk](https://bioventures.tech/tag/talk/)
- [Therapeutic Accelerator](https://bioventures.tech/tag/therapeutic-accelerator/)
- [ARHVA](https://bioventures.tech/tag/arhva/)
- [Application](https://bioventures.tech/tag/application/)
- [Licensing Agreement](https://bioventures.tech/tag/licensing-agreement/)
- [UCSF](https://bioventures.tech/tag/ucsf/)
- [AML](https://bioventures.tech/tag/aml/)
- [AR Health Venture Accelerator](https://bioventures.tech/tag/ar-health-venture-accelerator/)
- [AR Health Ventures Accelerator](https://bioventures.tech/tag/ar-health-ventures-accelerator/)
- [Drug Discovery](https://bioventures.tech/tag/drug-discovery/)
- [Accelerator](https://bioventures.tech/tag/accelerator/)
- [MIEHT](https://bioventures.tech/tag/mieht/)
- [Entrepreneurship](https://bioventures.tech/tag/entrepreneurship/)
- [Education](https://bioventures.tech/tag/education/)
- [Maternal Health](https://bioventures.tech/tag/maternal-health/)
- [Preventive Health](https://bioventures.tech/tag/preventive-health/)
- [IDHI](https://bioventures.tech/tag/idhi/)
- [Digital Health](https://bioventures.tech/tag/digital-health/)
- [Rural Health](https://bioventures.tech/tag/rural-health/)
- [ACTIVE](https://bioventures.tech/tag/active/)
- [ACTIVE Spotlight](https://bioventures.tech/tag/active-spotlight/)
- [Healthcare Entrepreneurship](https://bioventures.tech/tag/healthcare-entrepreneurship/)
- [Pregnancy Resources](https://bioventures.tech/tag/pregnancy-resources/)
- [Arkansas](https://bioventures.tech/tag/arkansas/)
- [Startup Support](https://bioventures.tech/tag/startup-support/)
- [Opportunity](https://bioventures.tech/tag/opportunity/)
- [Resources](https://bioventures.tech/tag/resources/)
- [IP](https://bioventures.tech/tag/ip/)
- [Healthcare](https://bioventures.tech/tag/healthcare/)
- [Program](https://bioventures.tech/tag/program/)
- [Spotlight](https://bioventures.tech/tag/spotlight/)
- [Postdoctoral](https://bioventures.tech/tag/postdoctoral/)
- [BioVentures](https://bioventures.tech/tag/bioventures/)
- [People](https://bioventures.tech/tag/people/)
- [Leadership](https://bioventures.tech/tag/leadership/)
- [Innovation Week](https://bioventures.tech/tag/innovation-week/)
- [Innovation Week 2025](https://bioventures.tech/tag/innovation-week-2025/)
- [Inentors](https://bioventures.tech/tag/inentors/)
- [Student Research Day](https://bioventures.tech/tag/student-research-day/)
- [Team](https://bioventures.tech/tag/team/)
- [Strategy](https://bioventures.tech/tag/strategy/)
- [Consultant](https://bioventures.tech/tag/consultant/)
- [Amy Hopper Swan](https://bioventures.tech/tag/amy-hopper-swan/)
- [Inventors](https://bioventures.tech/tag/inventors/)
- [Industry](https://bioventures.tech/tag/industry/)
- [Registrations Open](https://bioventures.tech/tag/registrations-open/)
- [tradespace](https://bioventures.tech/tag/tradespace/)
- [disclosure](https://bioventures.tech/tag/disclosure/)
- [invention disclosure](https://bioventures.tech/tag/invention-disclosure/)
- [software](https://bioventures.tech/tag/software/)
- [Trademark](https://bioventures.tech/tag/trademark/)
- [Copyright](https://bioventures.tech/tag/copyright/)
- [Tech Transfer](https://bioventures.tech/tag/tech-transfer/)
- [Technology Transfer](https://bioventures.tech/tag/technology-transfer/)
- [Inventors Handbook](https://bioventures.tech/tag/inventors-handbook/)
- [internship](https://bioventures.tech/tag/internship/)
- [intern](https://bioventures.tech/tag/intern/)
- [New Patent](https://bioventures.tech/tag/new-patent/)
- [Cancer](https://bioventures.tech/tag/cancer/)
- [Antibody](https://bioventures.tech/tag/antibody/)
- [Licensing](https://bioventures.tech/tag/licensing/)
- [PCAR](https://bioventures.tech/tag/pcar/)
- [Student](https://bioventures.tech/tag/student/)
- [Mentorship](https://bioventures.tech/tag/mentorship/)
- [Business](https://bioventures.tech/tag/business/)
- [Committee](https://bioventures.tech/tag/committee/)
- [HSE](https://bioventures.tech/tag/hse/)
- [expo](https://bioventures.tech/tag/expo/)
- [TRI Research Expo](https://bioventures.tech/tag/tri-research-expo/)
- [Networking](https://bioventures.tech/tag/networking/)
- [Inmunotherapy](https://bioventures.tech/tag/inmunotherapy/)
- [Small Molecule](https://bioventures.tech/tag/small-molecule/)
- [Talent](https://bioventures.tech/tag/talent/)
- [Susan Riley Keyes Memorial Fellowship](https://bioventures.tech/tag/susan-riley-keyes-memorial-fellowship/)
- [Job Post](https://bioventures.tech/tag/job-post/)
- [Research Program Manager](https://bioventures.tech/tag/research-program-manager/)
- [Job](https://bioventures.tech/tag/job/)
- [showcase](https://bioventures.tech/tag/showcase/)
- [medical](https://bioventures.tech/tag/medical/)
- [discoveries](https://bioventures.tech/tag/discoveries/)
- [Neurosurgery](https://bioventures.tech/tag/neurosurgery/)
- [Anxiety Reduction](https://bioventures.tech/tag/anxiety-reduction/)
- [Virtual Reality](https://bioventures.tech/tag/virtual-reality/)
- [Cadet](https://bioventures.tech/tag/cadet/)
- [translational](https://bioventures.tech/tag/translational/)
- [events](https://bioventures.tech/tag/events/)
- [Chancellor](https://bioventures.tech/tag/chancellor/)
- [Bio on the Bayou](https://bioventures.tech/tag/bio-on-the-bayou/)
- [Biotechnology](https://bioventures.tech/tag/biotechnology/)
- [Conference](https://bioventures.tech/tag/conference/)
- [New Orleans](https://bioventures.tech/tag/new-orleans/)
- [SBA](https://bioventures.tech/tag/sba/)
- [GAFCA](https://bioventures.tech/tag/gafca/)
- [Growth Accelerator Fund Competition Award](https://bioventures.tech/tag/growth-accelerator-fund-competition-award/)
- [Lab-toMarket](https://bioventures.tech/tag/lab-tomarket/)
- [Market](https://bioventures.tech/tag/market/)
- [Partnership](https://bioventures.tech/tag/partnership/)
- [Honors Track](https://bioventures.tech/tag/honors-track/)
- [Applications Open](https://bioventures.tech/tag/applications-open/)
- [Cell](https://bioventures.tech/tag/cell/)
- [Gene Therapy](https://bioventures.tech/tag/gene-therapy/)
- [Vaccine](https://bioventures.tech/tag/vaccine/)
- [Virus](https://bioventures.tech/tag/virus/)
- [Innovation Award](https://bioventures.tech/tag/innovation-award/)
- [BioVentures Innovation Award](https://bioventures.tech/tag/bioventures-innovation-award/)
- [Founder's Forum](https://bioventures.tech/tag/founders-forum/)
- [ARise](https://bioventures.tech/tag/arise/)
- [Issued Patent](https://bioventures.tech/tag/issued-patent/)
- [Neurodegenerative](https://bioventures.tech/tag/neurodegenerative/)
- [Protein](https://bioventures.tech/tag/protein/)
- [Disease](https://bioventures.tech/tag/disease/)
- [HSIE Grand Rounds](https://bioventures.tech/tag/hsie-grand-rounds/)
- [CEO](https://bioventures.tech/tag/ceo/)
- [Venture](https://bioventures.tech/tag/venture/)
- [Hackathon](https://bioventures.tech/tag/hackathon/)
- [AI](https://bioventures.tech/tag/ai/)
- [UALR](https://bioventures.tech/tag/ualr/)
- [Little Rock](https://bioventures.tech/tag/little-rock/)
- [HealthTech](https://bioventures.tech/tag/healthtech/)
- [Pitch Competition](https://bioventures.tech/tag/pitch-competition/)
- [Demo](https://bioventures.tech/tag/demo/)
- [Artificial Intelligence](https://bioventures.tech/tag/artificial-intelligence/)
- [NVIDIA](https://bioventures.tech/tag/nvidia/)
- [Free](https://bioventures.tech/tag/free/)
- [Multitool](https://bioventures.tech/tag/multitool/)
- [Therapy](https://bioventures.tech/tag/therapy/)
- [Badge](https://bioventures.tech/tag/badge/)
- [3D](https://bioventures.tech/tag/3d/)
- [Medical Student](https://bioventures.tech/tag/medical-student/)
- [Podcast](https://bioventures.tech/tag/podcast/)
- [Kevin Sexton](https://bioventures.tech/tag/kevin-sexton/)
- [Surgeon](https://bioventures.tech/tag/surgeon/)
- [Clinical](https://bioventures.tech/tag/clinical/)
- [Hardware](https://bioventures.tech/tag/hardware/)
- [Students](https://bioventures.tech/tag/students/)
- [Radiation](https://bioventures.tech/tag/radiation/)
- [Radiology](https://bioventures.tech/tag/radiology/)
- [ARGUS](https://bioventures.tech/tag/argus/)
- [Innovation Day 2026](https://bioventures.tech/tag/innovation-day-2026/)
- [ID2026](https://bioventures.tech/tag/id2026/)
- [Researcher](https://bioventures.tech/tag/researcher/)
- [Faculty](https://bioventures.tech/tag/faculty/)
- [Investor](https://bioventures.tech/tag/investor/)
- [Technology](https://bioventures.tech/tag/technology/)
- [Anthony Gunderman](https://bioventures.tech/tag/anthony-gunderman/)
- [Robotics](https://bioventures.tech/tag/robotics/)
- [Mechanical Engineering](https://bioventures.tech/tag/mechanical-engineering/)
- [Clinical Needs](https://bioventures.tech/tag/clinical-needs/)
- [Medical Technology](https://bioventures.tech/tag/medical-technology/)
- [Healthcare Innovation](https://bioventures.tech/tag/healthcare-innovation/)
- [Rural Robotics](https://bioventures.tech/tag/rural-robotics/)
- [Research & Innovation](https://bioventures.tech/tag/research-innovation/)
- [Engineering](https://bioventures.tech/tag/engineering/)
- [Technology Development](https://bioventures.tech/tag/technology-development/)
- [cardiac CT](https://bioventures.tech/tag/cardiac-ct/)
- [cardiovascular imaging](https://bioventures.tech/tag/cardiovascular-imaging/)
- [coronary computed tomography angiography](https://bioventures.tech/tag/coronary-computed-tomography-angiography/)
- [coronary artery disease imaging](https://bioventures.tech/tag/coronary-artery-disease-imaging/)
- [582](https://bioventures.tech/tag/582/)
- [U.S. Patent No. 12](https://bioventures.tech/tag/u-s-patent-no-12/)
- [374 B2](https://bioventures.tech/tag/374-b2/)
- [artificial intelligence in healthcare](https://bioventures.tech/tag/artificial-intelligence-in-healthcare/)
- [machine learning](https://bioventures.tech/tag/machine-learning/)
- [personalized motion-gated coronary CTA](https://bioventures.tech/tag/personalized-motion-gated-coronary-cta/)
- [motion-gated CT scanning](https://bioventures.tech/tag/motion-gated-ct-scanning/)
- [interventional cardiology](https://bioventures.tech/tag/interventional-cardiology/)
- [precision medicine](https://bioventures.tech/tag/precision-medicine/)
- [patient-specific imaging](https://bioventures.tech/tag/patient-specific-imaging/)
- [radiology innovation](https://bioventures.tech/tag/radiology-innovation/)
- [diagnostic radiology](https://bioventures.tech/tag/diagnostic-radiology/)
- [BioVentures Podcast](https://bioventures.tech/tag/bioventures-podcast/)
- [Marie Burdine](https://bioventures.tech/tag/marie-burdine/)
- [Organ Preservation](https://bioventures.tech/tag/organ-preservation/)
- [Delayed Graft Function](https://bioventures.tech/tag/delayed-graft-function/)
- [Transplant Research](https://bioventures.tech/tag/transplant-research/)
- [Kidney Transplantation](https://bioventures.tech/tag/kidney-transplantation/)
- [Drug Development](https://bioventures.tech/tag/drug-development/)
- [Graduate](https://bioventures.tech/tag/graduate/)
- [Deadline](https://bioventures.tech/tag/deadline/)
- [Bio International Convention](https://bioventures.tech/tag/bio-international-convention/)
- [San Diego](https://bioventures.tech/tag/san-diego/)
- [Convention](https://bioventures.tech/tag/convention/)
- [Academia](https://bioventures.tech/tag/academia/)
- [Government](https://bioventures.tech/tag/government/)
- [Alzheimer](https://bioventures.tech/tag/alzheimer/)
- [Prize](https://bioventures.tech/tag/prize/)
- [Sponsor](https://bioventures.tech/tag/sponsor/)
- [Megan Reed](https://bioventures.tech/tag/megan-reed/)
- [License](https://bioventures.tech/tag/license/)
- [NanO2](https://bioventures.tech/tag/nano2/)
- [Stroke](https://bioventures.tech/tag/stroke/)
- [NuvOx](https://bioventures.tech/tag/nuvox/)
- [Translational Science](https://bioventures.tech/tag/translational-science/)
- [DDFPe](https://bioventures.tech/tag/ddfpe/)
- [Innovation Day](https://bioventures.tech/tag/innovation-day/)
- [Awards](https://bioventures.tech/tag/awards/)
- [Recognition](https://bioventures.tech/tag/recognition/)
- [Community](https://bioventures.tech/tag/community/)
- [Registration](https://bioventures.tech/tag/registration/)